This is the Author's Accepted Manuscript of the following article: Lostalé-Seijo, I., & Montenegro, J. (2018). Synthetic materials at the forefront of gene delivery. Nature Reviews Chemistry. doi: 10.1038/s41570-018-0039-1

Synthetic Materials at the Forefront of Gene Delivery

Irene Lostalé-Seijo[†], **& Javier Montenegro**[†*]

[†] Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain. *e-mail: javier.montenegro@usc.es.

Abstract

The delivery of materials for genetic engineering with transitory activity constitutes a promising field in biology and medicine with potential applications in the treatment of disease, from cancer and infectious diseases to inheritable disorders. The possibility to restore the expression of a missing protein, the potential correction of the splicing of defective genes, or the silencing or modulation of the expression of other genes constitute powerful tools that will have a great impact in the future of biology and medicine. Impressive progress has been made in the last decade, with several products reaching the market as novel technologies for gene editing emerge. However, the transference of these technologies to functional therapies is hindered by the suboptimal performance of vehicles in capturing, protecting and delivering the corresponding nucleotide cargoes with safety and efficacy. Chemistry and the chemical sciences will play a key role in the development of the innovative synthetic materials that will overcome the upcoming challenges of the next generation gene delivery therapies and protocols. In this review we address the newest chemical advances in the production of materials at the forefront of nucleotide cell delivery and gene therapy.

1. Introduction

Chemistry and molecular biology have always been involved in the development of new technologies with potential therapeutic applications. DNA automated synthesis[1] has been essential for PCR[2], or site-directed mutagenesis[3]. These have allowed the generation of optimized fluorescent proteins[4], phage display technology[5], unnatural amino acids incorporation into proteins[6], catalytic antibodies[7,8] and synthetic genomes[9–11]. Among all of these discoveries and techniques, genetic engineering and gene therapy constitute one of the most promising technologies for the treatment of disease and for the future of human health[12–14]. The use of nucleic acids as therapeutic agents to repair a protein deficiency or to modulate gene expression has a great potential not only for the treatment of inherited disorders, but also in the treatment of acquired diseases through their utilization as DNA vaccines, antiviral therapies and cancer immunotherapy[13] (TABLE 1). However, the growth of the expectations in gene therapy and medicine have sometimes been dramatically crushed by the delivery problem[15]. Nucleic acids are negatively charged and are occasionally very unstable molecules and thus their intracellular delivery, at the right place at the right moment, still constitutes a challenge for synthetic chemistry, materials science and biotechnology.

A gene vector has to overcome different barriers before the successful delivery of its cargo (FIG. 1; TABLE 2). First, the nucleotide cargo should be protected from degradation, which is usually achieved by complexation or encapsulation in different structures[16]. The size and charge of these complexes has to be controlled as it affects uptake efficiency and bio-distribution, as too large or too small particles can be cleared by the mononuclear phagocyte system, the liver or the kidneys[16]. In systemic delivery, molecules larger than individual oligonucleotides cannot cross the endothelial barrier except for tissues with fenestrated or leaky vasculature[17]. Improving carrier selectivity by conjugation of the vector with targeting molecules can increase selectivity towards targeted cells increasing uptake and decreasing off-target effects[17]. Finally, vector particles have to translocate the plasma membrane, avoid endosomal entrapment and, in some cases, cross the nuclear envelope[16]. Moreover, the nucleotide cargo has to be released from the transported complexes to be free to interact with its target or be recognized by the cellular elements required for silencing, transcription or translation. Therefore, the delivery efficiency is not only a question of plasma membrane translocation and cellular internalization. The ideal gene carrier should be able to deliver different nucleic acids, protect the cargo from nucleases, avoid fast clearance, toxicity, and immune detection, prevent non-specific interactions with proteins and non-target cells, reach the cells of interest, escape the endosome, release the cargo and, when necessary, transport the cargo into the nucleus (TABLE 2)[16,18,19]. This is obviously not a simple task for synthetically scalable materials but the latest achievements in the field point to a promising future for the wide variety of non-viral vectors.

Viruses function as natural gene carriers as they are able to bind the cell membrane, internalize in the cell, and escape the endosome to reach the cytosol. As viruses survival requires the efficient delivery of their own genetic material into cells, they have been artificially manipulated for therapeutic gene transfection[20,21]. Therefore, some modified viral vectors have been approved for the treatment of human disease, such as Glybera for lipoprotein lipase deficiency[22], Gendicine for cancer treatment[23], or Luxturna for retinal dystrophy[24]. However, viruses and derived materials present drawbacks, mainly related with their low cargo capacity and their immunogenicity that can cause fatal adverse reactions or abrogate their activity, or require additional immunosuppresive therapy[14,25]. Furthermore,

the limitations in the large-scale production of viruses and their potential to induce undesired insertional mutagenesis strongly complicates their real applicability in gene therapy. For instance, Glybera has been withdrawn from the market due to the high production costs and lack of demand[26].

The combination of synthetic chemistry and molecular biology has been widely explored for the development of artificial carriers that could accomplish efficient and selective intracellular gene delivery[18,27–30]. Traditional non-viral vectors showed low efficiency due to low cell selectivity as well as endosomal entrapment. Additionally, most of the delivery studies are performed on monolayers of immortal cell lines that usually contain alterations in DNA/RNA sensing or survival pathways, which can overestimate their efficiency when transferred to *in vivo*[31]. Nevertheless, impressive conceptual advances in synthetic gene vehicles have emerged in the last few years and several compounds have shown good activity, not only *in vitro* but also *in vivo*. Nucleotide chemical modifications have delivered a new set of artificial nucleic acid analogues with higher stability, improved activity and lower immunogenicity[32]. Additionally, the current covalent and supramolecular synthetic tools allow the preparation of an unlimited number of new compounds that can be applied for the delivery of bioactive nucleotides. Nowadays, several formulations for gene-based therapies are reaching the clinic[33]. Although viral vectors predominate in the medical applications of gene therapy[34], synthetic vectors are becoming a real alternative in nucleotide-mediated therapeutics. For instance, naked antisense phosphorothioates have been recently approved for human use[35], non-viral siRNA delivery systems are being tested for cancer treatment[36,37], and Patisiran, a lipid nanoparticle for the delivery of siRNA for the treatment of hereditary transthyretin-mediated amyloidosis, has recently finished phase 3 studies[38]. This review will address the latest advances in non-viral gene delivery and we have sorted these synthetic carriers according to their chemical nature in order to highlight the importance of their molecular structure and connect this structural information to its particular functional application (TABLE 2).

Cargo	Description	Site of Activity	Function
Plasmid **Minicircles**	Large circular dsDNA molecules (several kb). Minicircles are usually smaller (no bacterial backbone). Need to reach the nucleus to be transcribed. Half-life in serum: 10-20 min[200]. Active in cells: some constructions can be active for months or years[19].	Nucleus	Expression of proteins to restore a function or to develop an immune response against it. Expression of regulatory RNAs. Some risk of insertional mutagenesis by recombination with cellular DNA.
mRNA **Replicon RNA**	Large ssRNA molecules: several kb, typically mRNA < 10 kb; replicon > 10 kb (includes gene sequence and non-structural replicase genes). Secondary structure may impact translation efficiency[28] Half-life in serum: seconds[201] Active in cells: from minutes to days[202]	Cytosol	Protein expression to restore function or to develop immune response against it. Replicon self-amplifies and extends the time protein is being expressed. No risk of recombination with cellular genome.
Antisense oligonucleotides **Splice correcting oligonucleotides**	Short DNA, RNA or analogues (15-30 nt) Half-life dependent on the chemistry of the backbone.	Cytosol/Nucleus	Mask alternative splice sites to produce the desired mRNA isoform (splice correcting oligonucleotides). Degradation of mRNA after forming DNA/RNA duplexes by RNaseH (antisense oligonucleotides). Inhibition of mRNA translation by steric hindrance (antisense oligonucleotides).
Short regulatory RNAs (siRNA, miRNA…)	Short (~21-22 bp) Half-life in serum: minutes, but it can be increased with backbone modifications[203] Active in cells: from days to months, depending on the mechanism of action[188]	Cytosol/Nucleus	Directs RISC complex to specific mRNAs for degradation (siRNA, cytosolic) Induces long-term silencing by DNA methylation (siRNA, nucleus). Regulates mRNA stability or translation (miRNA, cytosolic). Induces chromatin reorganization (miRNA, nucleus).
DNazyme, **RNazyme,** **MNazyme**	Short (~50-150 nt), typically with complicated secondary structures. Half-life dependent on the chemistry of the backbone	Cytosol/Nucleus	Nucleic acids with enzymatic activity, usually used as site specific nucleases. Composed of a single strand of DNA (DNazymes), RNA (RNazymes), or multiple strands (MNazymes).

Table 1. A brief description of the nucleic acids cargos mentioned in the text.

Barrier	Strategy	Examples	Ref
Nuclease degradation	Backbone modification	PS bonds and 2' modifications to reduce hydrolysis	[35,39–43]
	Covalent attachment of molecules	PEG brushes (pacDNA)	[56,57]
	Non-covalent interactions	Masking of siRNA by dsRNA binding proteins	[77,78]
		Inhibitory local high salt concentration in SNAs	[185–187,190–193]
		Complexation or encapsulation with different carriers	See section 2.3
Complexation and particle formation	Self-assembling oligonucleotides	PS-tcDNA	[40]
	Nucleic acid nanoparticles	DNA or RNA nanoparticles generated by RCA or RCT.	[58,59]
	Covalent attachment to polymers or nanoparticles	PEG-Brushes (pacDNA)	[56,57]
		Spherical nucleic acids	[185–187,190–193]
	Increased affinity for nucleic acids	Modification of peptides with guanidiniocarbonyl pyrrole	
		Polymer modification with zinc dipicolylamine	[138]
	Improved encapsulation methods	Enhancing encapsulation efficiency of exosomes by cholesterol modified siRNA	[126,127]
		High-yield encapsulation of siRNA in silica nanoparticles	[194]
	Other strategies	Complexation or encapsulation with different carriers	See section 2.3
Systemic distribution, targeting and toxicity problems	Increasing circulation time	Enhancing interaction with albumin or antibodies	[79–83]
	Reducing toxicity	Degradable nanoneedles to reduce inflammatory response	[67]
		Avoiding immune recognition of VLPs by shielding with polymers	[74]
		Slow release of polyplexes from silica nanoparticles.	[195]
		Fluorination of polymers and dendrimers	[145–147]
	Targeting to the desired cells or tissue	Recognition of membrane proteins by aptamers	[49–51,58,119]
		Recognition of membrane proteins by antibodies	[82,83]
		Recognition of ASGPR by tri-antennary-*N*-acetyl galactosamine	[52–54]
		Spatial control of the delivery by using ultrasound triggered release of microbubbles or liposomes	[68–70]
		Targeting peptides (RGD)	[130,131,182]
		Modification of the natural target of VLP and exosomes by surface modifications	[73,75,76,125]
		Recognition of specific cells with artificial modifications	[107,109]
Cellular uptake and release of the cargo	Backbone modifications	Gymnosis of phosphorothioate nucleotides	[35,39–43]
		Esterification to facilitate membrane crossing	[48]
	Endosomal escape	Physical methods	[66,67]
		Taking advantage of viral capsid proteins in VLP	[73,75,76]
		Avoiding endocytic pathways (peptide CLIP6)	[88,89]
		Protonable peptides, foldamers and dendrimers	[84,94–96,152]
		Ionizable lipids	[115,116,118]
		Topology mediated fusion	[110–113]
		pH triggered disassembly	[130–136,150]
		Fluorination of polymers and dendrimers	[145–147]
	Cargo release	Disulfide bonds	[60,138,139,147]
		Acid labile linkers	[61,150]
		Hydrazones	[97–99,155]
		pH-triggered disassembly	[133,135–137,191]
		Hyaluronidase mediated	[140]
		ATP-triggered disassembly	[141–143]
		Self-degrading polymers	[144]
		Fluorination of polymers and dendrimers	[145–147]
	Nuclear membrane	Electroporation and deformation	[66]
		Incorporation of peptides with NLS sequences	[165,188]

Table 2. Summary of the barriers for gene delivery and the strategies used by some of the non-viral gene carriers discussed in the text.



Figure 1. Different synthetic materials and current challenges for efficient intracellular gene delivery. The successful delivery of a functional nucleic acid requires overcoming important biological barriers. An initial condensation of the nucleotide cargo in particles of the right size and charge for delivery also contributes to the protection of the cargo against ubiquitous nucleases. The endothelial barrier, the hepatic and renal clearance, and the accumulation outside the target tissue might hinder the bioavailability of the therapeutic nucleotide in the *in vivo* systemic delivery. To reach its final intracellular destination, nucleotide vehicles have to cross the plasma membrane, escape from the endosome and cross the nuclear membrane, if necessary, for their activity.

2. Non-viral delivery methods

2.1. Artificial "self-delivering" oligonucleotides

Nucleotide chemical modifications. The activity and specificity of bioactive oligonucleotides depends mostly on their base sequence, while the biopolymer backbone usually plays a structural role. Therefore, nucleotides can tolerate the introduction of certain modifications on their structure that can improve their stability and uptake efficiency without affecting the recognition of its target. The chemical structure of oligonucleotide-based drugs has been in a state of permanent evolution to optimize their delivery and clinical applications[32]. Synthetically modified antisense oligonucleotides (ASOs) include, among others, phosphorothioate nucleotides (PS) in combination with locked nucleic acids (LNAs)[39], tricyclo-DNA oligomers (tcDNA)[40], 2'-O-(2-Methoxyethyl)-oligonucleotides (2'-O-MOE)[41] or 2'-deoxy-2'-fluoroarabinonucleotides (2'-F-ANA)[42] (FIG. 2a). The substitution of the oxygen for a sulphur atom in phosphorothioate-modified antisense oligonucleotides (PS-ASOs) strongly reduces their nucleolytic degradation. The spontaneous uptake, or gymnosis, of these stabilized single stranded nucleotides has been observed both *in vitro* and *in vivo*[39] and a number of formulations of phosphorothioate oligonucleotides have been approved for human use[35], such as Fomivirsen for the treatment of cytomegalovirus retinitis[43], or Mipomersen for homozygous familial hypercholesterolemia[41]. The inclusion of additional hydrophobic carbon atoms, between the C5' and C3' positions of the nucleotide of a phosphorothioate tricyclo-DNA (tcDNA), triggered its self-assembly into nanoparticles with a suitable size (40-100 nm) for *in vivo* delivery, and therapeutic improvement on a mouse model of Duchenne's muscular dystrophy[40]. However, nucleotide chemical modifications can sometimes give rise to adverse effects such as complement activation, trombocytopenia, increased off-target interactions, or intrinsic toxicity of the corresponding metabolites[44]. Particularly, modifications that increase nucleotide hydrophobicity at the 2' position such as in 2'-fluoro-modified phosphorothioate-ASOs[45] and phosphorothioate-LNAs[46] have been shown to be hepatotoxic in mice. Intriguingly, less hydrophobic modifications like in 2'-O-MOE (2'-*O*-(2-methoxyethyl)) or in constrained 2'-*O*-ethyl nucleotides did not show the same effect[45]. However, there is growing evidence that this toxicity, probably due to an increased affinity of these nucleotides towards the hepatic proteins, can be controlled by sequence design optimization[46].

Charge reduction. The highly negatively charged phosphate backbone of nucleic acids blocks their interaction with the anionic components of the membrane and hinders its crossing of the non-polar membrane[47], a situation that prevents the uptake of therapeutic oligonucleotides. The phosphate charges can be reduced by esterification and phosphotriester formation. The modification of the nucleotide phosphate, with the S-acyl-2-thioethyl (SATE) moiety,

was optimized for 2' modified nucleotides (2'-F or 2'-O-Me) by employing the mild basic-sensitive phenoxyacetyl protecting group, which avoids phosphotriester hydrolysis at the nucleobase deprotection step. Although it cannot be applied to the whole sequence due to duplex destabilization, this esterification strongly increased the nucleotide bioavailability by binding to serum albumin. Additionally, fusion to cell penetrating peptides (CPPs) or glycan moieties (i.e. tris-*N*-acetylgalactosamine) enhanced the cellular uptake of the resulting hybrid oligonucleotides[48]. This elegant strategy allowed the high yield production of neutral siRNA derivatives (siRNN), in which the artificial thioester can be de-caged by cytosolic thioesterases to regenerate the original fully functional siRNA inside cells[48] (FIG. 2b).

Programmable hybridization. The predictable and programmable folding of nucleotides can be employed to control the presentation of functional nucleotides and cell targeting sequences. This concept has been applied in gene targeted delivery by generation of active oligonucleotide/targeting aptamer chimeras such as aptamer-siRNA or aptamer-miRNA chimeras[49] (FIG. 2c). Analogously, a Y-shaped RNA scaffold containing anti miR-21 was combined with an EGFR aptamer, and the resulting chimera showed promising activity against breast cancer[50]. The programmable sequential recognition of a nanovehicle by two aptamers that are bound to two different cell receptors was employed for targeted gene delivery. The interaction of the nanovehicle with the first aptamer, bound to a cell surface receptor, cleaves a DNA loop by reconstitution of a MNAzyme. After this cleavage, a hybridization sequence of the nanovehicle is exposed and presented to the second aptamer that is bound to a different cell receptor. Hybridization with this second aptamer anchors the DNA nanovehicle to the membrane and enables specific endocytic internalization only in the cells where both receptors are present[51]. In addition to aptamers, fusion to other ligands can also be applied to trigger specific receptor-mediated endocytosis. The conjugation of antisense oligonucleotides or siRNA to tri-antennary-*N*-acetyl galactosamine is a widely used strategy for the targeted delivery to the hepatic asialoglycoprotein receptor (ASGPR)[52–54] (FIG. 2c). The attachment of this particular glycan has also been confirmed to reduce the toxicity of the oligonucleotide conjugates[55]. PEG brushes have been also connected to antisense DNA (pacDNA) to increase the stability of the bioactive nucleotide against nucleases and facilitate its cellular uptake by endocytosis[56,57] (FIG. 2d). Larger single stranded DNA or RNAs, generated by rolling circle amplification or transcription techniques[58,59], can fold into globular structures or “nanoflowers” (FIG. 2d). These nanoassemblies can include aptamer sequences for tumour targeting and DNAzymes to silence specific genes required for cell survival[58]. Similar stimuli-responsive RNA nanoparticles have been recently developed to release multiples copies of siRNA inside the cell[59]. These cleavable RNA nanoparticles consist of a long ssRNA containing repetitions of a siRNA antisense strand hybridized with chimeric DNA-RNA sense strands. These DNA/RNA duplexes were coated with a glutathione sensitive chitosan polymer for delivery and they were cleaved inside the cell by the cellular RNaseH[59].

Dynamic covalent linkers. Attaching large structures to a nucleotide cargo may impair its biological activity. Covalent dynamic linkers (i.e. disulfide) can be used to connect the nucleic acid and the non-viral vehicle. These dynamic linkers can be cleaved by external stimuli (i.e. proteases, pH changes, reducing agents) and thus release the intact nucleic acid material at the suitable tissue or intracellular location. A multifunctional cationic amphipathic polymer can be grafted, via pH or protease sensitive linkages, to PEG and *N*-acetylgalactosamine pendants and connected to a siRNA cargo by a disulfide bond[60]. In the first step, the protease or pH-mediated cleavage restored ligand targeting and membrane interaction and, once inside the cell, the cleavage of the disulfide bonds triggered cargo release[60]. In a different conceptual strategy, nucleic acids that are recognised by a polypeptide sequence can function as simple carriers for the delivery of transcription factors for gene expression regulation. In DNA assembled recombinant transcription factors (DARTs), the nucleic acid acts as a simple carrier and it can be decorated with glycan residues via a dynamic acetal linker that after hydrolysis unmasked hydrophobic endosomal disrupting domains to facilitate cargo delivery (FIG. 2e)[61].



158

159 **Figure 2. Modifications for self-delivering oligonucleotides. a)** Chemical modifications of nucleotides for
160 gymnotic delivery. These modifications usually involve a phosphorothioate backbone (left) combined with additional
161 modifications of the ribose, such as those pictured here. **b)** Phosphotriester modification reduces the negative charge
162 of the oligonucleotide and can be reversed by the activity of cellular thioesterases, to get the natural phosphodiester.
163 **c)** Examples of delivery systems that exploit cellular interaction for uptake, such as receptor-binding aptamers or
164 glycan moieties attached to siRNA. **d**) Formation of globular structures, by the folding of long ssDNA or ssRNA
165 strands obtained by rolling circle amplification or transcription (RCA or RCT) that can contain aptamer sequences or
166 multiple repetitions of the active sequence, or by attachment of polymeric brushes that turn antisense oligonucleotides
167 into compact particles. **e)** An example of the pH-sensitive dynamic linkers found in DARTs.

168 **2.2. Delivery assisted by physical methods**

169 The efficiency and low cost of physical gene transfection has recently triggered a rebirth of this field. Although with
170 certain limitations for *in vivo* applications, excluding cutaneous treatment[62] or local hydrodynamic gene delivery to
171 liver or muscle[63], physical methods can be very useful for *ex vivo* gene therapy. In *ex vivo* therapies, patient cells are
172 removed, modified (i.e. transfected) under *in vitro* conditions and then reinfused into the patient. Electroporation,
173 osmotic shocks or microinjection allow direct delivery of the oligonucleotide to the cytoplasm or nucleus,
174 circumventing any endosomal pathway and/or nuclear membrane barrier[64], because of the transient extensive
175 disruption of the plasma and nuclear membranes. However, this aggressive technique can lead to severe cellular
176 damage and new technologies are being developed to allow a better control of the degree of membrane disruption[64].
177 Indeed, physical gene delivery is currently in the pipeline for therapeutic applications such as cancer immunotherapy
178 by chimeric antigen receptors (CAR), in where the T-cells of a patient can be extracted, physically transfected *ex vivo*
179 and the new reprogrammed T-cells re-injected into the same patient to seek and destroy the tumour[65]. Recently, the
180 combination of electroporation and microfluidic cell deformation has been explored for high throughput plasmid,
181 mRNA or protein delivery[66]. The application of nanoneedles in drug and gene delivery is generally associated with
182 inflammation[62] which can be useful for vaccination but undesirable for other purposes. Biodegradable porous silicon
183 nanoneedles have recently been developed, which increases their *in vivo* tolerance and safety[67], and extends their
184 potential applications. The collapse of gas-filled microbubbles, under target-directed ultrasound, was applied in
185 systemic delivery of drugs[68]. However, the stabilization of microbubbles for DNA delivery usually requires
186 microbubble functionalization with binary lipid mixtures to avoid perturbation of their acoustic properties[68]. A recent
187 screening of these stabilizing lipids identified a single dimyristoyl cationic lipid branched with polyspermine and
188 partially decorated with PEG. This single lipid formulation was able to deliver a miniplasmid to hepatocytes
189 achieving long term gene expression[69]. Microbubbles can also be used for the targeted delivery of promiscuous
190 cationic liposomes[70]. These plasmid loaded cationic liposomes can be functionalized with PEG and heparin to inhibit

191 off-target uptake. The precise ultrasonic disruption of co-injected microbubbles triggered the local release of the
192 liposomal contents[70]. Acoustic transfection, directly based on membrane disruption due to cavitation, can also
193 achieve *in vitro* plasmid, mRNA or protein transfection with single cell resolution[71].

194 **2.3. Carrier mediated**

195 ***2.3.1. Protein based***

196 **Virus-like particles**. Protein vehicles can also be employed to protect and deliver bioactive nucleotides. The
197 encapsulation of nucleotidic cargo into a protein container is a ubiquitous strategy in nature in viruses and in higher
198 organisms[72]. For instance, the Arc protein, evolutionary related to transposon's gag protein, forms enveloped virus-
199 like particles that are able to deliver its own mRNA across neurons or the neuromuscular junction in mammals and
200 insects[72]. Virus like particles (VLPs) that are reconstructed from proteins of the natural virus can encapsulate active
201 oligonucleotides, inhibiting tumour growth by intracellular delivery of a suicide gene[73]. Interestingly, the strong
202 immunogenicity of VLPs can be reduced by particle surface modification with polymers such as polynorbornene or
203 polyethylenglycol[74]. Decoration of VLPs with targeting moieties can redirect these artificial capsids to other tissues,
204 as was demonstrated by the attachment of transferrin or aptamers to polyomavirus VLPs[75] or phages[76].

205 **RNA binding proteins**. dsRNA-binding domains are common in proteins of viral and non-viral origin and can be
206 used for siRNA protection and delivery (FIG. 3a). A fusion protein composed of dsRNA-binding domains, from the
207 protein kinase PKR, fused to a penetrating peptide sequence, was confirmed to deliver siRNA in hard-to-transfect
208 cells and *in vivo* by intranasal inoculation[77]. To achieve an efficient intracellular siRNA delivery, the binding between
209 the protein and the nucleotide has to be strong enough to protect the cargo, but it also has to be disrupted in the last
210 step of the delivery process. A systematic study using high-affinity dsRNA binding proteins, derived from p19 of
211 *Carnation Italian Ringspot Virus*¸ showed that, even for dissociation constants in the low pM range, the inhibitory
212 binding-limit was not reached[78]. However, to achieve cytosolic delivery of the siRNA in this study a second pore
213 forming Perfringolysin O protein was required to achieve endosomal escape[78].

214 **Bioavailability enhancers**. Association with certain proteins can improve cargo pharmacokinetics, as the bigger
215 protein/cargo complexes can circumvent renal clearance and extend their serum half-life by the exocytosis-recycling
216 pathway. The non-covalent binding of lipid modified oligonucleotides to albumin has been applied to enhance the
217 bioavailability of siRNA[79,80] and other antisense oligonucleotides[81]. Conjugation of nucleotides to antibodies can also
218 provide improved pharmacokinetics and targeting capacities. A fusion protein composed of HIV specific F105
219 antibody fragment and protamine, as a nucleic acid binding protein, was designed and confirmed to deliver a siRNA
220 specifically to HIV infected cells[82]. After attachment of siRNA to antibodies, by redox sensitive disulfides in
221 THIOMAB antibodies, no improvement in activity was found between a dynamic linker and a covalent connector.
222 These results indicate that a reversible bond is not a prerequisite for activity[83], as the linker is at the sense strand and
223 it might not affect the antisense strand loading into the RISC complex. However, in all these examples of protein
224 mediated delivery, the endosomal escape is usually the limiting factor and the addition of endosomolytic agents as
225 pore forming toxins[78] or CPPs[77] is sometimes required to achieve efficient cargo delivery.

226 ***2.3.2. Peptides***

227 Cell penetrating peptides (CPPs) have been extensively applied to the delivery of nucleic acids[84,85], as covalent or
228 non-covalent conjugates. Recent research on CPPs has focused on the development of new synthetic peptides for the
229 delivery of artificial nucleotides (TABLE 3). Artificial PMO nucleotides have been conjugated to peptides of the Pip
230 family[86] and arginine-rich peptides[87] that include non-proteinogenic aminoacids such as 6-aminohexanoic or β-
231 alanine. The resulting conjugates achieved therapeutic levels of cargo delivery in different animal models of muscular
232 dystrophies[86,87]. The cationic amphiphilic CLIP6 cell penetrating peptide presents a D-proline at the middle of its
233 sequence, together with a glutamic acid that disrupt its potential β-sheet secondary structure[88]. This "*intrinsically*
234 *disordered*" peptide was able to reach the cell cytosol by a non-endocytic mechanism[88] for PNA efficient delivery[89].
235 Amphiphilic peptide nanofibers, composed of a short cationic sequence and a β-sheet seed followed by a
236 hydrophobic tail, can also be employed for slow release of antisense oligonucleotides *in vitro*[90] and for localized
237 siRNA delivery *in vivo* by stereotactic surgery[91]. Peptide nanofibrils[92] or nanosheets[93] can be implemented as
238 enhancers of viral gene transfer[92]. These amyloids have the ability to concentrate and increase infectivity of
239 lentiviruses, a very promising technology with multiple potential *ex vivo* applications[92]. In the RALA peptide, a
240 variant of the amphiphilic GALA[84], the protonation of glutamate residues prevents the anionic repulsion between
241 peptide side chains and triggers helical folding. This secondary structure fluctuation allows membrane disruption at
242 low pH and RALA mediated intracellular delivery of plasmids[94] or mRNA[95]. Artificial non-peptidic foldamers have
243 also emerged as biocompatible vehicles for gene delivery. Disulfide connected dimers of amphiphilic oligourea
244 helical foldamers, equipped with imidazole and isopropyl moieties, were recently shown to deliver plasmid DNA in

cells with low toxicity[96]. Dynamic bonds such as oximes or hydrazones are formed in mild aqueous conditions, with good yields, short reaction times and in a fully bio-orthogonal fashion. Combinations of cationic hydrophilic peptides with hydrophobic tails of different lengths and properties have allowed the straightforward screening and quick identification of new simple formulations for siRNA[97], plasmid[98] or Cas9 delivery[99]. The recently introduced guanidiniocarbonylpyrrole group can form four hydrogen bonds with the phosphate of nucleotides[100] (FIG. 3b) and thus enhance the plasmid delivery capabilities of short peptides[101]. Cyclic peptides of alternating chirality[102] incorporating guanidiniocarbonylpyrrole can self-assemble into fibers that can also be applied in plasmid transfection[100]. Alternation of guanidiniocarbonylpyrrole and cyclohexylalanine afforded large amyloid peptide fibers that can be further processed with gold nanoparticles to obtain nanoparticles of the right size for cell transfection[103]. Another recent and interesting approach is the use of peptides with biological activity as carriers[104]. For instance, the peptide PepM, derived from a Dengue virus protein, reduces by itself the number of mitotic cells and can also be used for siRNA delivery in combined therapy[104].

Peptide	Sequence	Notes
Pip6[86]	RXRRBRRXRYQFLIRXRBRXRB	X = aminohexanoic acid, B = β-alanine
Peptide B[87]	RXRRBRRXRRBRXB	X = aminohexanoic acid, B = β-alanine
CLIP6[88,89]	KVRVRVRVpPTRVRERVK	p = D-Proline Cross directly the cell membrane.
Lys-PA[90]	Lauryl-VVAGK	Nanofibers forming peptide.
PNF[91]	Palmitoyl-GGGAAAKRK	Nanofibers forming peptide
EF–C^{+2} [92]	QCKIKQIINMWQ	Derived from HIV gp120. Enhances retroviral infection.
Amyloid-forming heptapeptide[93]	KLVFFAK	Derived from the Italian familial form of Alzheimer's Aβ. Enhances retroviral infection
RALA[94,95]	WEARLARALARALARHLARALARALRACEA	Derived from GALA peptide.
PepM[104]	KLFMALVAFLRFLTIPPTAGILKRWGTI	Residues 45–72 of Dengue virus 2C protein. Perturbs Bcr-Abl1 signalling.

Table 3. Selected examples of peptide sequences for gene delivery.

2.3.4. Lipid based

Enhancing membrane fusion. Lipofection has been one of the most popular methods of transfection since the discovery that cationic lipids spontaneously condense DNA and fuse with cell membranes[105]. Current efforts in this field are focused on enhancing the fusogenic properties of the liposomes and minimizing their toxicity. In most cases, membrane fusion of liposomes is optimized to overcome the endosomal entrapment, while direct fusion with plasma membrane and subsequent direct delivery in the cytosol has received much less attention[106]. Inspired by SNARE proteins responsible for vesicle fusion in cells, artificial liposomes exposing one of the peptides of a coiled-coil motif specifically delivered siRNA and splice correcting oligonucleotides in cells that were previously loaded with the corresponding coil counterpart peptide[107] (FIG. 3c). The application of this methodology has allowed the preparation of different fusogenic peptide liposomes for the direct intracellular release of vesicular contents[108]. Cell surface engineering by ketone-containing lipids has been recently applied to cell transfection with the corresponding lipoplex containing bio-orthogonal reactive alkoxyamine functionalities[109] (FIG. 3d). However, the *in vivo* application of these creative approaches will require the challenging selective ketone-lipid or coil modification of the target cells[107,109]. The lipid transfection helper DOPE bears two bulky oleyl hydrophobic tails giving rise to a conical shape lipid that tends to assemble into the less stable hexagonal phase instead of the lamellar phase adopted by other lipids with higher head to tail surface ratio[110,111]. The Safinya group recently demonstrated that inverse bicontinuous gyroid cubic nanostructures, confirmed by X-ray scattering, could also enhance fusion with the endosome membrane and efficiently deliver siRNA without the requirement of a high cationic charge[112] (FIG. 3e). Although these cuboplexes were not able to transport longer DNAs, they can be further modified with PEG for additional stabilization without activity loss, pointing towards future *in vivo* applications[113].

Lipid nanoparticles engineering. Lipid nanoparticles can be modified by using mixtures of different lipids in which not only the lipid composition, but also the synthesis method, can have a great impact on the size, the biodistribution and the delivery efficiency[114]. Typically, they contain a pegylated lipid, cholesterol, a helper lipid and an ionizable lipid. The cross-reaction of alkylamines with alkylacrylates with different hydrophobic tails generated a library of ionizable lipidoids that were combined with cholesterol, DSPC and PEG-DMG to formulate nanoparticles for siRNA delivery. This strategy allowed the extraction of structural insights about ionizable lipid nanoparticles for endosomal escape and for *in vivo* delivery. The most effective formulations included lipidoids with three or more hydrophobic tails, secondary and tertiary amines and a particle surface pK_a of around 5.5-7[115]. Recent studies on ionizable lipids

287 also stressed the importance of tertiary amines and the steric constraints for the conformational switch of the lipids
288 that triggers endosomal escape by changing the relative orientation of the hydrocarbon chains[116] (FIG. 3f). The net
289 surface charge of liposomes can alter their biodistribution, as shown by DOTMA and DOPE mixed liposomes that
290 accumulated in the lung when having a positive charge or in the spleen as the negative charges increased. This
291 property was exploited to deliver mRNA to dendritic cells for the development of mRNA vaccines against cancer[117].
292 In a similar strategy, lipid nanoparticles containing phospholipids, ionizable and PEG-modified lipids, cholesterol,
293 and a lipopolysaccharide adjuvant, were loaded with mRNA and the subcutaneous injection of these liposomes
294 triggered an immune response that could overcome the critical self-tolerance against auto-antigens required in cancer
295 immunotherapy[118]. Thiol-conjugated lipids/aptamers can be also assembled into nanoparticles and employed in
296 targeted delivery of siRNA to different tissues such as bone to improve osteogenesis[119]. Polydiacetylenic derivatives
297 with protonable amine or imidazol groups can be crosslinked with UV light to generate interesting structures, such as
298 nanomicelles[120,121] or nanofibers[122] that are suitable for plasmid and siRNA delivery. The clinical potential of lipid
299 engineering is exemplified by Patisiran, a siRNA drug against hereditary transthyretin-mediated amyloidosis, which
300 is delivered by lipid nanoparticles containing DLin-MC3-DMA[38,123].

301 **Exosomes and Sterosomes**. Exosomes are naturally produced vesicles containing lipids, proteins and nucleic acids
302 that can act as natural carriers of proteins and nucleic acids. Generally, extravesicular engineering has been carried
303 out by the loading of exogenous agents and by the genetic engineering of parental cells[124]. However, until recently
304 the chemical modification of exosomes for gene delivery has been surprisingly overlooked. In an interesting
305 biotechnological strategy, fusogenic liposomes were used to load the membrane of living cells with azide modified
306 artificial lipids. The chemically modified exosomes produced by these cells can then be easily further functionalized
307 by click chemistry, for example by conjugation with targeting peptides[125]. In recent examples, the loading of
308 exosomes with synthetic oligonucleotides was simplified by the use of hydrophobic cholesterol-modified
309 siRNA[126,127]. Despite their promising properties, the cellular origin of exosomes constitutes an important challenge in
310 terms of their large-scale production with standard sizes and compositions. Sterosomes, cationic liposomes enriched
311 in steroles and stearylamine, can provide a more stable alternative to phospholipid liposomes, as they are less affected
312 by hydrolysis and oxidation[128] (FIG. 3g). Sterosomes have been embedded in hydrogels for sustained noggin siRNA
313 delivery to enhance osteogenic differentiation during bone regeneration[128].

314



315

316 **Figure 3. Peptide and lipid based delivery systems. a)** dsRNA binding proteins can be used for the recognition and
317 delivery of siRNA. **b)** Guanidiniocarbonylpyrrole (GPC), showing the four potential hydrogen bonds that can be
318 established with the phosphate backbone. **c)** Mechanism of fusion enhancement between cellular membranes and
319 liposomes, by exploiting the formation of coiled-coils of peptides present in the liposome carrier and the cell
320 membrane target. According to the cartoon, the helical wheel representation of the coil of the vesicle (in blue) and the
321 coil of the cell membrane (in red) include the following amino acids: hydrophobic (A, L, I in black), cationic (K in
322 purple) and anionic (E in orange). **d)** Bio-orthogonal reaction between the alkoxyamine bearing lipids of the liposome
323 vehicle and a cell membrane loaded with lipids exposing ketone groups. **e)** Structure of cuboplexes, whose topology
324 allows membrane fusion without the requirement of a high cationic charge (reproduced with permission from REF.
325 112; Copyright © 2010, American Chemical Society). **f)** Ionizable lipids contain a head with protonable groups and
326 flexible bonds that allow conformational changes when the head is protonated. The conformational change induced
327 by protonation in the lipid library synthesized by Viricel *et al*. is depicted. **g)** Sterosomes are alternatives to
328 phospholipid liposomes prepared by mixing stearylamine with esteroles such as cholesterol and its derivatives.

329 ### *2.3.5. Polymers, dendrimers and micelles*

330 **pH disassembly**. Polymers can display, in a multivalent fashion, the functionalities that are required for membrane
331 recognition, interaction and translocation. This structural versatility and the potential synthetic scalability turn
332 synthetic polymers into one of the most promising artificial materials for gene delivery. The current research efforts
333 in polymeric materials for gene delivery are focused on improving condensation of the cargo, the reduction of the
334 toxicity and the enhancement of the endosomal escape. To achieve these challenging goals, new polymers have been
335 designed to disassemble upon the exposure to external stimuli such as reducing agents, enzymes, light, temperature,
336 and above all, pH. The cooperative pH triggered disassembly of poly(2-(diisopropylamino) ethylmethacrylate)
337 (PDPA) offers an excellent conceptual advance for micelle disruption and cargo release at the tumour
338 microenviroment[129] (FIG. 4a). This concept was exploited in PDPA ultrasensitive pH co-polymers containing RGD

339 peptide, PEG, and grafted with cationic lipid-like structures[130,131]. The resulting grafted nanoparticles showed a very
340 narrow pH triggered disassembly at the pH of the early endosome that was employed for *in vivo* siRNA tumour
341 targeted delivery[130,131]. In an analogous approach, the pK_a of low uptake cationic micelles was tuned by adjusting the
342 ratios of its components (PDPA and PDMAEMA). At the optimal pK_a (6.8-7), an excellent siRNA delivery was
343 observed even at low cellular uptake or in hard-to-transfect cells[132]. The pH-dependent aggregation of oligo-
344 ethyleneimines (OEI) was optimized by the attachment of different aromatic pendants, such as salicylate (SaOEI), to
345 maximize the pH-triggered disassembly and cargo release of polyplexes with different nucleic acids[133] (FIG. 4a). The
346 pH-triggered dissociation of polyplexes can also be used to release a hidden membrane-lytic peptide to enhance
347 nucleotide release[134]. This method avoided the membrane disruption until the complex reached the endosome and
348 thus reduced the toxicity of the final formulation[134]. A different pH-triggered strategy to change polymer properties,
349 from hydrophobic to hydrophilic, to trigger polyplex disassembly and plasmid delivery, explored the pH dependent
350 cleavage of benzoic aromatic imines to generate cationic amines[135]. Charge altering releasable transporters (CARTs)
351 are composed of oligo(carbonate-*b*-alpha-amino ester) and a lipophilic block. CARTs polymers lose their charge and
352 self-immolate at cytosolic pH, by intramolecular amide formation and piperazines release, to efficiently deliver
353 mRNA both *in vitro* and *in vivo*[136] (FIG. 4a). Self-replicating alphavirus replicons are large RNA molecules that can
354 sustain prolonged protein expression but they do not tolerate structural chemical modifications. To protect them from
355 nucleases, these replicons can be formulated with cationic ionizable dendrimeric poly(amido amine) and pegylated
356 lipids before intramuscular injection for their *in vivo* use as RNA vaccines[137].

357 **Redox, enzymes and other strategies for polyplex disassembly.** Several other strategies have been studied to
358 trigger nucleotide release from polymeric formulations. The disulfide bond can also be exploited in polymers that
359 disassemble in the reducing cytosolic environment. The transfection efficiency of branched PEI was enhanced by
360 polymer disulfide functionalization with zinc dipicolylamine analogues, which increases vehicle DNA affinity,
361 membrane binding and transfection efficiency[138] (FIG. 4b). Pegylated polymers, carrying dithiolane rings for
362 disulfide crosslinking, can be assembled into nanoparticles loaded with siRNA (FIG. 4b). These nanoparticles were
363 decorated with tumour targeting peptides and showed virus-like cell attachment and "*capsid uncoating*" behaviour in
364 the cytosol[139]. In a different enzymatic disassembly strategy, a core-shell artificial virus was prepared by covering a
365 fluorinated cationic polymer and a DNA core with an outer shell made of a polymer of hyaluronan with PEG and R8-
366 RGD peptides. The degradation of this layered polyplex was mediated by the hyaluronidase overexpressed in the
367 tumour environment, which exposed the particle core and allowed the *in vivo* delivery of problematic large
368 plasmids[140]. Polyols, including siRNA, can be stabilized by reversible ester formation of the 2-*cis*-diols of the
369 terminal ribose or other polymers with phenylboronate[141]. After uptake, these boronate-stabilized particles can be
370 disrupted by the high levels of internal ATP triggering siRNA[142] or plasmid release[143] (FIG. 4b). In other cases,
371 instead of a stimulus, timed degradation can be used to protect the cargo until cytosolic delivery. This is true in the
372 case of poly(2-dimethylaminoethyl acrylate) (PDMAEA), a cationic polymer that slowly self-degrades into a
373 negatively charged compound that repels its cargo for siRNA release[144] (FIG. 4b).

374 **Fluorinated dendrimers and polymers.** PAMAM perfluorinated dendrimers condensate plasmid DNA at very low
375 N/P ratios, reducing its positive charge and thus lowering toxicity and increasing efficiency in the presence of
376 serum[145,146]. Their hydrophobic and lipophobic properties reduce their membrane interactions and increase their
377 ability to penetrate tissues and spheroids[146]. This intriguing principle was applied in bioreducible PEI micelles with a
378 perfluorinated core that showed good activity in DNA delivery[147]. Polymer fluorination has also shown excellent
379 potential for the delivery large plasmids[140] and proteins[148].

380 **Supramolecular chemistry and dynamic chemistry.** Weak non-covalent bonds like electrostatic and hydrophobic
381 interactions control the dynamic processes of nucleotide complexation, protection, membrane translocation and
382 complex disassembly. Therefore, supramolecular chemistry and supramolecular templates are powerful tools to
383 understand and to develop conceptually new non-viral vectors. Cyclodextrin-based carriers consist of a linear cationic
384 polymer containing cyclodextrins that can complex with siRNA and then incorporate targeting and stabilizing
385 moieties by supramolecular host-guest chemistry with adamantane conjugates[36,149]. This modular strategy originally
386 developed by Mark Davis[149] has been recently modified by using non-polymeric cyclodextrin with LMW PEI
387 pendants that are stabilized with pH sensitive polyketal poly-adamantanes[150] (FIG. 4c). Cyclodextrins polymers have
388 also been recently used in tumour targeted combined therapy with a chemotherapeutic agent and plasmid DNA[151].
389 Amphiphilic polymers with a hydrophobic core, capped with dendronized dipeptides, enriched in aromatic tryptophan
390 or pH responsive histidine residues, performed as good *in vitro* delivery vectors for siRNA[152]. However,
391 cyclodextrins have recently showed toxicity problems in phase one clinical trials[37]. The use of thiol click-chemistry
392 allows the fast preparation of libraries of polyesters for siRNA delivery that can show selectivity to tumour
393 cells[153,154]. Hydrazone-modulated polymers have also been recently introduced as a promising alternative to screen
394 for polymer nucleotide vehicles. In this strategy, poly-hydrazides can be modified with different combinations of

cationic and hydrophobic aldehydes to generate a library of amphiphilic polymers that can complex and deliver siRNA and plasmid in living cells[155,156] (FIG. 4d).

Combined therapies. In several recent examples, the polymer can also play an active role and contribute to an additional therapeutic function instead of acting as a mere carrier. PolyMetformin, derived from the anticancer and antidiabetic drug metformin (dimethyl biguanide), has the ability to complex siRNA while preserving its anticancer properties and it can be formulated with lipids and co-delivered into tumour cells[157] (FIG. 4e). A dendronized dithiophene semiconducting polymer can also deliver a plasmid and trigger the expression of genes regulated by heat shock proteins by near infrared photothermal activation[158].

Glycan, protein and antibody conjugates. *N*-acetyl-D-galactosamine pendants have been incorporated in guanidinium polymers to enhance targeting and reduce toxicity in the transfection of HepG2 cells[159]. Similar behaviour has been observed in poly(glycoamidoamines) and PEI derived polymers that incorporate carbohydrate (D-glucaric acid) co-monomers[160]. These materials have been further modified by adding alkyl chains to obtain polymer brush materials loaded with siRNA, mRNA and lipids to produce nanoparticles with *in vivo* activity[161]. The introduction of alkyl chains to enable self-assembly with other hydrophobic compounds, such as pegylated lipids, has been applied to poly(β-amino esters) (PBAE), to generate nanoparticles to deliver mRNA to the lungs[162]. Another problem with mRNA delivery is that certain cationic carriers can mask the m7G cap at the 5’ end, blocking its recognition by cellular proteins and inhibiting mRNA translation. To improve translation initiation, mRNA can be pre-assembled with eIF4E, the protein involved in cap recognition, a technique that enhanced mRNA expression, both *in vivo* and *in vitro*[163]. Programmable self-assembly was exploited to prepare dendrimeric siRNAs that were efficiently complexed to PBAE polymers or branched and linear PEI[164]. PBAE polymers containing peptides with microtubule-associated sequences and nuclear localization signals were employed to overcome the limitation of crossing the nuclear membrane for plasmid delivery in non-dividing cells[165]. In a recent and extraordinarily promising approach, a plasmid DNA packed with this PBAE polymer was coated with poly(glutamic) acid fused to a targeting antibody and the resulting polyplex allowed *in vivo* reprogramming of T-cells with CARs for the treatment of a leukemia model[165].



Figure 4. Polymeric approaches to gene delivery. a) Structures of pH-sensitive polymers. PDPA gets protonated at low pH and electrostatic repulsion disassembles the polymeric structure. Salicylic acid modification of oligoethyleneimine (SaOEI) reduces its affinity for nucleic acids at low pH and contributes to the disassembly of the polyplexes. CARTs are self-immolative polymers that degrade at pH higher than 7. **b)** Polymers that respond to other stimuli. Disulfide bonds can be used for disassembly in the reducing conditions of the cytosol, as in the case of zinc-dipicolylamine modified PEI or dithiolane rings that can be introduced in the polymer sequence for crosslinking and stabilization of the nanoparticles. Cationic PDMAEA spontaneously degrades into the negatively charged poly(acrylic acid). ATP responsive polymers are based on the reversible interaction of phenylboronic acid with diols. **c)** Cyclodextrins can be incorporated into cationic polymers (left) and then modified with different compounds (PEG, targeting moieties...) using adamantane or another hydrophobic residue that interact with the cyclodextrin. Alternatively, individual cyclodextrins can be decorated with shorter cationic polymers for nucleic acid interaction and then assembled into larger structures using poly-adamantanes (right). **d)** Conceptual scheme for dynamic polyhydrazones. Dynamic hydrazide polymers can be combined with different aldehydes to afford cationic amphiphilic polyhydrazone for nucleotide delivery. (Reproduced with permission from REF. 155). **e)** Example of a polymeric nucleotide vehicle, polyMetformin, that presents intrinsic biological activity for combined therapy.

2.3.5. Nanoparticles

Carbon allotropes. The use of inorganic structures for plasmid delivery can be loosely tracked back to the 70s, with the development of the calcium phosphate co-precipitation method for DNA delivery into cells[166]. Since then, the nanoparticle field has evolved tremendously with substantial improvements being made in the characterization of nano-structures and the implementation of novel functionalities. Carbon nanoforms constitute promising materials for a range of diagnostic tools and biomedical therapies[167]. The potential toxicity of carbon nanostructures can be modulated by controlling the size and by modifying the surface of the nanoparticles, and thus chemistry plays a key role in turning carbon allotropes into biocompatible scaffolds[167]. In gene delivery, chemically functionalized carbon nanotubes (CNs) exploit their high aspect ratio to rupture or to slip through the lipid bilayer (FIG. 5a). The 1,3-dipolar cycloaddition of carbon nanotubes with azomethine ylides can be employed to equip CNs with pendants of oligoethyleneglycol bearing terminal amines for the binding and delivery of DNA plasmids[168]. The carboxylic groups at the tips of oxidized CNs allow the attachment of ammonium and guanidinium dendrons by amide bond formation

or click chemistry for siRNA complexation and delivery[169]. In an alternate approach to covalent modification, supramolecular hydrophobic interactions between CNs and lipid/PEG amphiphiles can also be employed to stabilize CNs in water and functionalize them by disulfide bonds with a siRNA cargo[170]. As the bio-distribution of CNs is influenced by their width[171] or length[172], this property can be exploited in targeted gene delivery[172]. Recent studies have shown that CNs have the ability to insert and cross the *zona pellucida* to deliver DNA into embryos without the requirement of individual manipulation[173]. Cationic fullerenes, such as the tetra(piperazino)fullerene epoxide, can efficiently condense and deliver a plasmid DNA with suitable low toxicity when used *in vivo*[174]. Polycationic fullerene hexakis-adducts have also been employed in plasmid transfection *in vitro*[175]. The ROS generation of fullerenes when excited by light can also be exploited to enhance the endosomal escape of siRNA for cationic dextran decorated fullerene vehicles[176]. Conjugation of CPPs to graphene oxide nanosheets reduces CPP toxicity and increases their activity for delivering pDNA and ASO, but not siRNA[177]. Nanodiamonds, a potentially more biocompatible carbon allotrope, can also be complexed to nucleic acids when decorated with amines[178] or cationic polymers[179–181] (FIG. 5b). The polymer pendants can be covalently attached by reaction with the carboxylated diamond surface[179] or non-covalently conjugated by the electrostatic interactions between the cationic polymer and the anionic oxidized nanodiamond[180,181].

Metal Nanoparticles. The precise control of size, shape and the responsiveness to external stimuli are examples of the critical features that metal nanoparticles offer for biomedical applications. Additionally, the surface of metal particles can be straightforwardly functionalized with different bioactive and biocompatible targeting molecules. The thiol-gold linkage constitutes a simple and reliable method for the functionalization and modification of gold nanoparticles (FIG. 5c). Tissue-targeting of siRNA was achieved by the thiol-gold connection of metal nanoparticles and a block copolymer shell of poly-L-lysine-poly-ethylenglycol terminated by cyclic RGD peptides[182] (FIG. 5c, left). The embedding of gold nanoparticles in hydrogels has been applied for colon cancer treatments by triple-combination therapy (siRNA, drug and phototherapy). This multifunctional approach involved gold nanorods decorated with the Avastin antibody drug against VEGF and the colorectal cancer targeting peptide TCP-1. The nanorods were combined with gold nanospheres that were covered with siRNA and further functionalized with endosomolytic peptides for improved release[183]. Gold nanoclusters, prepared by glutathione and oligoarginine controlled Au^{3+} reduction, have been recently confirmed as excellent siRNA delivery vehicles for silencing the NGF gene against the challenging pancreatic cancer[184] (FIG. 5c, middle).

Spherical Nucleic Acids. The tightly packing of nucleic acids over the surface of nanoparticles gives rise to spherical shaped nucleic acids conjugates (SNAs) with interesting properties such as increased stability, enhanced affinity and the ability to transfect cells despite their negative surface charge due to potential interaction with scavenger receptors[185]. Different SNAs with gold cores have been used for the delivery of siRNA[186–188] (FIG. 5c, right) or ribozymes[189] into cells and animals. Topical wound application of SNAs made of oligoethylene glycol and siRNA (against GM3S) restores wound healing in diabetic mice[186]. SNAs surface modification with nuclear localization signal peptides (NLS) strongly enhanced nuclei siRNA delivery and induced long term gene silencing by RNA-directed DNA methylation[188]. Although SNAs were initially assembled on gold nanoparticles[185], further studies confirmed that their emerging properties were independent from the metal core. These findings triggered the emergence of more biocompatible cores such as DNA[190], polymers (HOPO[191]), liposomes[192] or other structures (POSS[193]). These “organic” SNAs have been successfully tested in siRNA delivery[190–193].

Porous particles. Mesoporous silica nanoparticles can achieve an extremely high siRNA loading capacity of up to 380 µg/mg[194]. Such porous nanoparticles can be grafted with silanes (APTES, TEOS, MPTES) to modify their surface with amino and mercapto-groups (FIG. 5d). siRNA was then loaded by incubation in solution at low pH and the particles were finally covered with a block copolymer that was further modified with hydrophobic oleic pendants and terminal cysteines for cross-linking. The final silicon based porous ensemble achieved one of the highest siRNA delivery efficiencies described for silica nanoparticles[194]. A similar porous silicon platform can also be functionalized with aminopropyl-triethoxysilane (APTES), followed by amide connection with L-arginine and PEI. The pores of the cationic silicon carrier were loaded with siRNA, which was released in the form of polyplexes after silicon degradation. The prolonged slow release of these polyplexes reduced the toxicity of the formulation after systemic injection[195]. APTES grafted silica nanoparticles can be also functionalized by coordination with Ce^{3+} for further anchoring of branched PEI polymer. The resulting nanoparticles (SPA-Ce-PEI) delivered siRNA with higher efficiency than branched PEI alone[196]. Anionic mesoporous silicon nanoparticles, decorated with ICP (3-isocyanatopropyltriethoxysilane), can be covered with cyclodextrin-grafted polyethylenimine. Doxorubicin was then encapsulated in the porous nanomaterial and the resulting nanoparticles were applied to the delivery of a cytotoxic drug and a siRNA against PKM2 in combined therapy against orthotopic breast tumours[197]. Metal organic frameworks (MOFs) constitute promising scaffolds for nucleotide encapsulation and delivery due to their controlled porosity. Zr^{4+} based MOFs were applied in combined therapy for the co-delivery of a *cis*-platin pro-drug and a

siRNA[198]. In a similar strategy, cysteine grafted MOFs were filled with Se or Ru because of their ability to disrupt microtubules and act as antitumour agents. These MOFs were also loaded with VEGF siRNA by the coordination of the vacant Fe(III) sites with the nucleotide phosphates. The final nanoparticles were applied for combined therapy against multidrug resistance breast cancer cells[199] (FIG. 5d).



Figure 5. Nanoparticles for gene delivery. a) Covalent and non covalent modifications of carbon nanotubes for the delivery of nucleic acids. **b)** Surface functionalization of nanodiamonds for nucleic acid interactions. **c)** Delivery systems involving gold nanoparticles: a gold nanoparticle modified with a targeting motif (cRGD), PEG and polylysine for siRNA binding[182]; gold nanoclusters formed by reduction in the presence of glutathione and oligoarginine[184] and an example of spherical nucleic acids[186], in which siRNA is bound to the nanoparticle through a thiol group and decorated with PEG; **d)** Porous nanoparticles. Left: Metal-organic framework (MIL-101) incorporating Se or Ru ions for microtubule disruption and siRNA. Right: Surface functionalization of mesoporous silica nanoparticles. Coordination via Cerium of PEI (SPA-Ce-PEI), engraftment with APTES, or further modification of APTES with arginine and PEI to generate PCPS (polycation-functionalized nanoporous silicon) to obtain the positive charge necessary for nucleic acids interaction, or introduction of thiol groups with MPTES for crosslinking with other polymers.

3. Discussion and outlook

The increasingly active field of non-viral gene delivery holds great promise for the future of biotechnology and human health. The improvement of the synthetic methods has recently granted the access to new encouraging molecular entities and nucleotide modifications such as phosphotriesters[48] or guanidiniocarbonylpyrrole groups[101]. Furthermore, the recent advances in microscopy and cell biology have allowed a higher level of understanding of the highly dynamic mechanism of uptake and escape of the cargo. These and other advances continuously assist and push chemists and material scientists to design and develop the next generation of non-viral carriers that can be sensitive to critical stimuli such as the specific pH required for disassembly[132] or the optimal pK_a of the lipid nanoparticles surface for enhanced uptake[115].

A clear trend for the future of the field will be the combination of new materials with novel formulation techniques. By blurring the barriers between different categories, the strength of each material can compensate the weakness of its counterpart and thus improve the performance of the final functional composite. Endosomolytic peptides buried in pH-sensitive micelles[134], polymer-coated silica nanoparticles[194] or peptide-lipid hybrids[98] are just a few recent examples that outline potential directions of the field. Additionally, combined therapy emerges as an encouraging strategy in where the nucleic acid function is supplemented with other therapeutics such as bioactive polymers[157] and co-delivery of cytotoxic agents[197]. Furthermore, the still mostly unexplored combination of chemically modified nucleotides and the next generation of synthetic transporters constitute a promising strategy to tackle the future challenges of synthetic materials at the forefront of gene delivery. Combinatorial libraries and high-throughput screening also constitutes an important and complementary technique compared to rational design, as it can identify structure-activity relationships and lead to unexpected results[97–99,115,116,153-155].

Importantly, the synthesis and formulation of the nanocarriers has to be scalable, reproducible and stable and although the field strongly demands new conceptual designs and strategies, the transference of these technologies to therapeutic applications will require a careful consideration of the synthetic scaling up process. In lipid particles, film hydration is sensitive to organic contaminants and in batch ethanol dilution homogeneous mixing is hard to achieve. Therefore, crossflow or microfluidics constitutes an excellent alternative for reproducibility and scalability[107,109,112–118,123]. The standard electrostatic complexation of nucleotides with polymers or peptides requires a good control of mixing and thus concentrations, charge ratios and pH and ionic strength have to be carefully considered[94,95,97–102,130–133,136,145,146]. Polyplex stability upon dilution is lower than for other formulations, although PEGylation might improve this situation. In gold nano-conjugates, salt reduction followed by ligand exchange or direct reduction with thiolated ligands can be potentially scaled up[182–184,186–188]. However, the election of the method in this case, will depend on the availability of the suitable thiolated ligands. Silica nanoparticles seem also promising scalable materials as they can be prepared by condensation of inexpensive silicates under different conditions[194–197].

It seems nowadays clear that not all *in vitro* results will work *in vivo*. Most of the *in vitro* experiments have been done in serum free conditions on immortalized cell lines that usually contain alterations that affect their ability to detect nucleic acids and enhance the cells tolerance to stress. These critical points for *in vitro* studies could lead to an overestimation of the delivery efficiency and an underestimation of the vehicle toxicity. Better *in vitro* models, such as primary cell cultures[77,136,138], or spheroids[80,146] may predict better the outcome of *in vivo* experiments, but they still lack the complexity of a living organism. In addition, the translation of these results to the clinic will always have to pass regulatory challenges, as all new formulations must be proven safe before further testing, and in this regard, formulations related to well established technologies, such as lipid-based carriers, will be in an advantageous position. So far, the most advanced methods in the race for clinical application[34] of non-viral vectors are phosphorothioates, naked plasmid DNA, lipid-based carriers and, to a lesser extent, polymeric carriers[34–38], which have already some examples approved[35] or nearly approved[38] for human use. The simplicity of the method of delivery of the naked cargo and the strong experience with liposomal-based drug delivery vehicles justify their predominance. On the other hand, non-biodegradable nanoparticles (i.e. carbon nanotubes, fullerenes, metal nanoparticles, etc.) may be problematic in the long-term, especially in cases where repeated administration may be necessary, as they tend to accumulate in liver and kidneys. To address this concern, there are several initiatives that try to replace the metal core of SNAs for biocompatible alternatives[190–193]. However, it is also possible that the therapeutic use of non-biodegradable nanoparticles might be restricted to cases in which the nature of the particle contributes to the treatment, as in photothermal therapy[183].

Despite impressive advances in the last decade, there are still considerable challenges that need to be met to help broaden the scope of potential future therapeutic applications of non-viral vectors such as vehicle bioavailability[79–81], reduction of immune response[32,74], balance of stability and release[40–42,58,78,115] and endosomal escape[95,132,135]. In this regard, the growing number of synthetic materials for the efficient *in vivo* transfection of hard-to-transfect cells

578 demonstrates the enormous power of chemistry and biology working together (TABLE 4). All these great advances
579 help inspire new approaches to gene therapy and bring hope for the future of human health[165].

580

Vector	Particle size	Serum Stability	Tolerability	Capacity	Scalability	Targeting	*In vivo* application*
Self-delivering oligonucleotides	PS-tcDNA: 40-100 nm	Variable depending on the modifications.	Potential problems by unwanted protein interactions.	Limited by the synthetic method; typically short.	Yes, but modified nucleotides increase costs.	Yes, by attaching ligands.	Some approved for human use[35,41]
Physical methods	Delivery of the naked cargo. Microbubbles (~2-7 µm) and liposomes (~100-200 nm)	For liposomes, > 30 min.	For ultasound targeted microbubble disruption, potential liver damage. With degradable nanoneedles, less inflammation than with classical nanoneedles.	From ASO/siRNA to pDNA.	Yes	Local administration with nanoneedles, or spatial control through target directed ultrasounds.	Transfection of skin and muscle of mice with nanoneedles[67]. Transfection with ultrasound in mice[68–70] Potential *ex vivo* applications for microfluidic systems[66]
Protein based methods	For VLPs, depends on the virus used. In other cases, soluble.	Increased stability.	Low toxicity	Depends on the protein used: in viral capsid, several kilobases, for dsRNA binding proteins and modified oligonucleotides, short sequences.	Potential limitations by protein purification.	By viral tropism, targeting ligands, by fusion to antibodies or by EPR (albumin).	i.v.[73,79–83] and intranasal[77] inoculation in mice.
Peptides	50 nm to several µm (fibers).	Several days in serum.	From low to moderately toxic.	From ASO/siRNA to pDNA. In peptide-oligonucleotide conjugates, length is limited by the synthetic method.	Yes, but in some cases synthesis can be expensive.	With targeting sequences or ligands.	i.c.[91], i.v. [86,94], and intradermal[95] injection of mice. i.v., i.c. or i.m. in dogs[87]
Lipid-based	50-400 nm	Variable depending on nanoparticle composition	Low toxicity, except for highly cationic particles.	From ASO/siRNA to pDNA.	Yes, although procedures that require sonication can be hard to scale up.	By EPR or with targeting ligands.	i.v.[115–117], s.c.[118] and combined with hydrogels[128] in mice; lipid nanoparticles in clinical trials[34]
Polymers, dendrimers and micelles	From 10 nm (smallest dendrimers) to almost 1 µm (fibers and large polyplexes). Typically 50-300 nm	Several hours	Most polymers are very biocompatible, but some toxicity issues have been observed (immune response, cytotoxicity...)	From ASO/siRNA to pDNA.	Yes, although some of the more complex formulations can be challenging.	By EPR,with targeting ligands or stimuli responsive motifs.	i.c. [135], i.p.[122], i.m.[133,136,137], i.t.[134,146], i.v.[130,131,136,139,140,149,151,157,165] in mice. Some reached clinical trial strage[36], but were retired because of adverse effects[37].
Nanoparticles	From 20 nm (SNAs) to 60 µm (CNs)	From hours to days	In general, inert and with low toxicity, but hard to degrade in the body. Some carbon allotropes can be toxic depending on functionalization and contaminants from synthesis.	From ASO/siRNA to pDNA.	Yes, but influenced by the modifications.	With targeting ligands, EPR, size... in some cases light stimulation.	i.v.[172,174,184,195,197,199], s.c.[176] or topically in mice[186]; bovine embryo transfection[173].

581 **Table 4. A brief summary of the different categories discussed on the text. *** i.c.: intracranial, s.c.: subcutaneous, i.p.: intraperitoneal, i.m.: intramuscular, i.v.: intravenous.

Acknowledgements

This work was partially supported by the Spanish Agencia Estatal de Investigación (AEI) [CTQ2014-59646-R, SAF2017-89890-R], the Xunta de Galicia (ED431G/09, ED431C 2017/25 and 2016-AD031) and the ERDF. J.M. received a Ramón y Cajal (RYC-2013-13784), an ERC Starting Investigator Grant (DYNAP-677786) and a Young Investigator Grant from the Human Frontier Science Research Program (RGY0066/2017).

589 1. Matteucci, M. D. & Caruthers, M. H. Synthesis of deoxyoligonucleotides on a polymer
590 support. *J. Am. Chem. Soc.* **103,** 3185–3191 (1981).

591 2. Saiki, R. K. *et al.* Primer-directed enzymatic amplification of DNA with a thermostable
592 DNA polymerase. *Science* **239,** 487–91 (1988).

593 3. Hutchison, C. A. *et al.* Mutagenesis at a specific position in a DNA sequence. *J. Biol.*
594 *Chem.* **253,** 6551–6560 (1978).

595 4. Heim, R. & Tsien, R. Y. Engineering green fluorescent protein for improved brightness,
596 longer wavelengths and fluorescence resonance energy transfer. *Curr. Biol.* **6,** 178–182
597 (1996).

598 5. Barbas, C. F., Kang, A. S., Lerner, R. A. & Benkovic, S. J. Assembly of combinatorial
599 antibody libraries on phage surfaces: the gene III site. *Proc. Natl. Acad. Sci. U. S. A.* **88,**
600 7978–82 (1991).

601 6. Wang, L., Brock, A., Herberich, B. & Schultz, P. G. Expanding the genetic code of
602 Escherichia coli. *Science* **292,** 498–500 (2001).

603 7. Lerner, R. A., Benkovic, S. J. & Schultz, P. G. At the crossroads of chemistry and
604 immunology: catalytic antibodies. *Science* **252,** 659–67 (1991).

605 8. Siegel, J. B. *et al.* Computational Design of an Enzyme Catalyst for a Stereoselective
606 Bimolecular Diels-Alder Reaction. *Science* **329,** 309–313 (2010).

607 9. Wang, L. *et al.* Synthetic Genomics: From DNA Synthesis to Genome Design. *Angew.*
608 *Chem. Int. Ed. Engl.* **57,** 1748–1756 (2018).

609 10. Gibson, D. G. *et al.* Creation of a Bacterial Cell Controlled by a Chemically Synthesized
610 Genome. *Science* **329,** 52–56 (2010).

611 11. Annaluru, N. *et al.* Total synthesis of a functional designer eukaryotic chromosome.
612 *Science* **344,** 55–8 (2014).

613 12. Naldini, L. Gene therapy returns to centre stage. *Nature* **526,** 351–360 (2015).

614 13. Dunbar, C. E. *et al.* Gene therapy comes of age. *Science* **359,** eaan4672 (2018).

615 14. Sheridan, C. Gene therapy finds its niche. *Nat. Biotechnol.* **29,** 459–459 (2011).

616 15. Jenks, S. Gene therapy death--"everyone has to share in the guilt". *J. Natl. Cancer Inst.*
617 **92,** 98–100 (2000).

618 16. Wang, T., Upponi, J. R. & Torchilin, V. P. Design of multifunctional non-viral gene
619 vectors to overcome physiological barriers: Dilemmas and strategies. *Int. J. Pharm.* **427,**
620 3–20 (2012).

621 17. Juliano, R. L. The delivery of therapeutic oligonucleotides. *Nucleic Acids Res.* **44,** 6518–
622 6548 (2016).

623 18. Yin, H. *et al.* Non-viral vectors for gene-based therapy. *Nat. Rev. Genet.* **15,** 541–555
624 (2014).

625 19. Hill, A. B., Chen, M., Chen, C. K., Pfeifer, B. A. & Jones, C. H. Overcoming gene-delivery
626 hurdles: Physiological considerations for nonviral vectors. *Trends Biotechnol.* **34,** 91–

627 105 (2016).

628 20. Giacca, M. & Zacchigna, S. Virus-mediated gene delivery for human gene therapy. *J.*
629 *Control. Release* **161,** 377–388 (2012).

630 21. Merten, O.-W. & Gaillet, B. Viral vectors for gene therapy and gene modification
631 approaches. *Biochem. Eng. J.* **108,** 98–115 (2016).

632 22. Melchiorri, D. *et al.* Regulatory evaluation of Glybera in Europe - two committees, one
633 mission. *Nat. Rev. Drug Discov.* **12,** 719 (2013).

634 23. Peng, Z. Current status of gendicine in China: recombinant human Ad-p53 agent for
635 treatment of cancers. *Hum. Gene Ther.* **16,** 1016–27 (2005).

636 24. Russell, S. *et al.* Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in
637 patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled,
638 open-label, phase 3 trial. *Lancet* **390,** 849–860 (2017).

639 25. Kaiser, J. A second chance. *Science* **358,** 582–585 (2017).

640 26. Senior, M. After Glybera's withdrawal, what's next for gene therapy? *Nat. Biotechnol.*
641 **35,** 491–492 (2017).

642 27. Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic
643 mRNA delivery. *Nat. Rev. Mater.* **2,** 17056 (2017).

644 28. Kaczmarek, J. C., Kowalski, P. S. & Anderson, D. G. Advances in the delivery of RNA
645 therapeutics: from concept to clinical reality. *Genome Med.* **9,** 60 (2017).

646 29. Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R. & Blankschtein, D. mRNA
647 vaccine delivery using lipid nanoparticles. *Ther. Deliv.* **7,** 319–334 (2016).

648 30. Stanton, M. G. Current Status of Messenger RNA Delivery Systems. *Nucleic Acid Ther.*
649 **28,** 158–165 (2018).

650 31. Hartung, T. & Daston, G. Are in vitro tests suitable for regulatory use? *Toxicol. Sci.* **111,**
651 233–237 (2009).

652 32. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of
653 clinical utility. *Nat. Biotechnol.* **35,** 238–248 (2017).

654 33. Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A. & Herzog, R. W. Clinical
655 development of gene therapy: results and lessons from recent successes. *Mol. Ther.*
656 *Methods Clin. Dev.* **3,** 16034 (2016).

657 34. Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy
658 clinical trials worldwide to 2017: An update. *J. Gene Med.* **20,** e3015 (2018).

659 35. Stein, C. A. & Castanotto, D. FDA-Approved Oligonucleotide Therapies in 2017. *Mol.*
660 *Ther.* **25,** 1069–1075 (2017).

661 36. Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered
662 siRNA-based therapeutics in cancer. *Nat. Rev. Drug Discov.* **14,** 843–56 (2015).

663 37. Barata, P., Sood, A. K. & Hong, D. S. RNA-targeted therapeutics in cancer clinical trials:
664 Current status and future directions. *Cancer Treat. Rev.* **50,** 35–47 (2016).

665 38. Adams, D. & Ole, S. Patisiran, an investigational RNAi therapeutic for patients with
666 hereditary transthyretin-mediated (hATTR) amyloidosis : Results from the phase 3
667 APOLLO study. *Rev. Neurol. (Paris).* **174,** S37 (2018).

668 39. Stein, C. A. *et al.* Efficient gene silencing by delivery of locked nucleic acid antisense
669 oligonucleotides, unassisted by transfection reagents. *Nucleic Acids Res.* **38,** e3 (2010).

670 40. Goyenvalle, A. *et al.* Functional correction in mouse models of muscular dystrophy
671 using exon-skipping tricyclo-DNA oligomers. *Nat. Med.* **21,** 270–5 (2015).

672 41. Geary, R. S., Baker, B. F. & Crooke, S. T. Clinical and Preclinical Pharmacokinetics and
673 Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense
674 Oligonucleotide Inhibitor of Apolipoprotein B. *Clin. Pharmacokinet.* **54,** 133–146 (2015).

675 42. Souleimanian, N. *et al.* Antisense 2'-deoxy, 2'-fluoroarabino nucleic acid (2'F-ANA)
676 oligonucleotides: In vitro gymnotic silencers of gene expression whose potency is
677 enhanced by Fatty Acids. *Mol. Ther. - Nucleic Acids* **1,** 1–9 (2012).

678 43. Azad, R. F., Brown-Driver, V., Buckheit, R. W. & Anderson, K. P. Antiviral activity of a
679 phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA
680 when used in combination with antiviral nucleoside analogs. *Antiviral Res.* **28,** 101–111
681 (1995).

682 44. Chi, X., Gatti, P. & Papoian, T. Safety of antisense oligonucleotide and siRNA-based
683 therapeutics. *Drug Discov. Today* **22,** 823–833 (2017).

684 45. Shen, W. *et al.* Acute hepatotoxicity of 2' fluoro-modified 5–10–5 gapmer
685 phosphorothioate oligonucleotides in mice correlates with intracellular protein binding
686 and the loss of DBHS proteins. *Nucleic Acids Res.* **46,** 2204–2217 (2018).

687 46. Burdick, A. D. *et al.* Sequence motifs associated with hepatotoxicity of locked nucleic
688 acid—modified antisense oligonucleotides. *Nucleic Acids Res.* **42,** 4882–4891 (2014).

689 47. Fuertes, A., Juanes, M., Granja, J. R. & Montenegro, J. Supramolecular functional
690 assemblies: dynamic membrane transporters and peptide nanotubular composites.
691 *Chem. Commun.* **53,** 7861–7871 (2017).

692 48. Meade, B. R. *et al.* Efficient delivery of RNAi prodrugs containing reversible charge-
693 neutralizing phosphotriester backbone modifications. *Nat. Biotechnol.* **32,** 1256–1261
694 (2014).

695 49. McNamara, J. O. *et al.* Cell type–specific delivery of siRNAs with aptamer-siRNA
696 chimeras. *Nat. Biotechnol.* **24,** 1005–1015 (2006).

697 50. Shu, D. *et al.* Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast
698 Cancer Utilizing RNA Nanotechnology. *ACS Nano* **9,** 9731–9740 (2015).

699 51. Ren, K. *et al.* A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery.
700 *Nat. Commun.* **7,** 13580 (2016).

701 52. Schmidt, K. *et al.* Characterizing the effect of GalNAc and phosphorothioate backbone
702 on binding of antisense oligonucleotides to the asialoglycoprotein receptor. *Nucleic*
703 *Acids Res.* **45,** 2294–2306 (2017).

704 53. Tanowitz, M. *et al.* Asialoglycoprotein receptor 1 mediates productive uptake of N-

705 acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense
706 oligonucleotides into liver hepatocytes. *Nucleic Acids Res.* **45,** 12388–12400 (2017).

707 54. Zlatev, I. *et al.* Reversal of siRNA-mediated gene silencing in vivo. *Nat. Biotechnol.* **36,**
708 (2018).

709 55. Huang, Y. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid
710 Therapeutics. *Mol. Ther. - Nucleic Acids* **6,** 116–132 (2017).

711 56. Lu, X. *et al.* Effective Antisense Gene Regulation via Noncationic, Polyethylene Glycol
712 Brushes. *J. Am. Chem. Soc.* **138,** 9097–9100 (2016).

713 57. Jia, F. *et al.* Depth-Profiling the Nuclease Stability and the Gene Silencing Efficacy of
714 Brush-Architectured Poly(ethylene glycol)–DNA Conjugates. *J. Am. Chem. Soc.* **139,**
715 10605–10608 (2017).

716 58. Jin, Y. *et al.* Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer
717 therapy. *NPG Asia Mater.* **9,** e365 (2017).

718 59. Lee, J. H. *et al.* Rolling circle transcription-based polymeric siRNA nanoparticles for
719 tumor-targeted delivery. *J. Control. Release* **263,** 29–38 (2017).

720 60. Rozema, D. B. *et al.* Protease-triggered siRNA delivery vehicles. *J. Control. Release* **209,**
721 57–66 (2015).

722 61. Lee, K. *et al.* In vivo delivery of transcription factors with multifunctional
723 oligonucleotides. *Nat. Mater.* **14,** 701–706 (2015).

724 62. McCaffrey, J., Donnelly, R. F. & McCarthy, H. O. Microneedles: an innovative platform
725 for gene delivery. *Drug Deliv. Transl. Res.* **5,** 424–437 (2015).

726 63. Suda, T. & Liu, D. Hydrodynamic gene delivery: Its principles and applications. *Mol.*
727 *Ther.* **15,** 2063–2069 (2007).

728 64. Stewart, M. P. *et al.* In vitro and ex vivo strategies for intracellular delivery. *Nature* **538,**
729 183–192 (2016).

730 65. Markey, P. M. *et al.* Driving CAR T-cells forward. *Nat. Rev. Clin. Oncol.* **6,** 300–308
731 (2015).

732 66. Ding, X. *et al.* High-throughput nuclear delivery and rapid expression of DNA via
733 mechanical and electrical cell-membrane disruption. *Nat. Biomed. Eng.* **1,** 0039 (2017).

734 67. Chiappini, C. *et al.* Biodegradable silicon nanoneedles delivering nucleic acids
735 intracellularly induce localized in vivo neovascularization. *Nat. Mater.* **14,** 532–539
736 (2015).

737 68. Anderson, C. D., Moisyadi, S., Avelar, A., Walton, C. B. & Shohet, R. V. Ultrasound-
738 targeted hepatic delivery of factor IX in hemophiliac mice. *Gene Ther.* **23,** 510–519
739 (2016).

740 69. Manta, S. *et al.* Cationic microbubbles and antibiotic-free miniplasmid for sustained
741 ultrasound–mediated transgene expression in liver. *J. Control. Release* **262,** 170–181
742 (2017).

743 70. Chertok, B., Langer, R. S. & Anderson, D. G. Spatial Control of Gene Expression by

744 Nanocarriers Using Heparin Masking and Ultrasound-Targeted Microbubble
745 Destruction. *ACS Nano* **10,** 7267–7278 (2016).

746 71. Yoon, S., Wang, P., Peng, Q., Wang, Y. & Shung, K. K. Acoustic-transfection for genomic
747 manipulation of single-cells using high frequency ultrasound. *Sci. Rep.* **7,** 5275 (2017).

748 72. Pastuzyn, E. D. *et al.* The Neuronal Gene Arc Encodes a Repurposed Retrotransposon
749 Gag Protein that Mediates Intercellular RNA Transfer. *Cell* **172,** 275–288.e18 (2018).

750 73. Chen, L. S. *et al.* Efficient gene transfer using the human JC virus-like particle that
751 inhibits human colon adenocarcinoma growth in a nude mouse model. *Gene Ther.* **17,**
752 1033–1041 (2010).

753 74. Lee, P. W. *et al.* Polymer Structure and Conformation Alter the Antigenicity of Virus-like
754 Particle-Polymer Conjugates. *J. Am. Chem. Soc.* **139,** 3312–3315 (2017).

755 75. Zackova Suchanova, J., Neburkova, J., Spanielova, H., Forstova, J. & Cigler, P.
756 Retargeting Polyomavirus-Like Particles to Cancer Cells by Chemical Modification of
757 Capsid Surface. *Bioconjug. Chem.* **28,** 307–313 (2017).

758 76. Tong, G. J., Hsiao, S. C., Carrico, Z. M. & Francis, M. B. Viral Capsid DNA Aptamer
759 Conjugates as Multivalent Cell-Targeting Vehicles. *J. Am. Chem. Soc.* **131,** 11174–11178
760 (2009).

761 77. Eguchi, A. *et al.* Efficient siRNA Delivery into Primary Cells by Peptide Transduction-
762 dsRNA Binding Domain (PTD-DRBD) Fusion Protein. *Nat. Biotechnol.* **27,** 567–571
763 (2009).

764 78. Yang, N. J. *et al.* Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding
765 proteins. *Nucleic Acids Res.* **45,** 7602–7614 (2017).

766 79. Bienk, K. *et al.* An albumin-mediated cholesterol design-based strategy for tuning siRNA
767 pharmacokinetics and gene silencing. *J. Control. Release* **232,** 143–151 (2016).

768 80. Sarett, S. M. *et al.* Lipophilic siRNA targets albumin in situ and promotes bioavailability,
769 tumor penetration, and carrier-free gene silencing. *Proc. Natl. Acad. Sci. U. S. A.* **114,**
770 E6490–E6497 (2017).

771 81. Hvam, M. L. *et al.* Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum
772 Albumin Constructs for Pharmacokinetic Modulation. *Mol. Ther.* **25,** 1710–1717 (2017).

773 82. Song, E. *et al.* Antibody mediated in vivo delivery of small interfering RNAs via cell-
774 surface receptors. *Nat. Biotechnol.* **23,** 709–717 (2005).

775 83. Cuellar, T. L. *et al.* Systematic evaluation of antibody-mediated siRNA delivery using an
776 industrial platform of THIOMAB-siRNA conjugates. *Nucleic Acids Res.* **43,** 1189–1203
777 (2015).

778 84. Lehto, T., Ezzat, K., Wood, M. J. A. & El Andaloussi, S. Peptides for nucleic acid delivery.
779 *Adv. Drug Deliv. Rev.* **106,** 172–182 (2016).

780 85. Tai, W. & Gao, X. Functional peptides for siRNA delivery. *Adv. Drug Deliv. Rev.* **110–111,**
781 157–168 (2017).

782 86. Hammond, S. M. *et al.* Systemic peptide-mediated oligonucleotide therapy improves
783 long-term survival in spinal muscular atrophy. *Proc. Natl. Acad. Sci. U. S. A.* **113,** 10962–

784 10967 (2016).

785 87. Echigoya, Y. *et al.* Effects of systemic multiexon skipping with peptide-conjugated
786 morpholinos in the heart of a dog model of Duchenne muscular dystrophy. *Proc. Natl.*
787 *Acad. Sci.* **114,** 4213–4218 (2017).

788 88. Medina, S. H. *et al.* An Intrinsically Disordered Peptide Facilitates Non-Endosomal Cell
789 Entry. *Angew. Chemie - Int. Ed.* **55,** 3369–3372 (2016).

790 89. Soudah, T., Mogilevsky, M., Karni, R. & Yavin, E. CLIP6-PNA-Peptide Conjugates: Non-
791 Endosomal Delivery of Splice Switching Oligonucleotides. *Bioconjug. Chem.* **28,** 3036–
792 3042 (2017).

793 90. Bulut, S. *et al.* Slow release and delivery of antisense oligonucleotide drug by self-
794 assembled peptide amphiphile nanofibers. *Biomacromolecules* **12,** 3007–3014 (2011).

795 91. Mazza, M., Hadjidemetriou, M., De Lázaro, I., Bussy, C. & Kostarelos, K. Peptide
796 nanofiber complexes with siRNA for deep brain gene silencing by stereotactic
797 neurosurgery. *ACS Nano* **9,** 1137–1149 (2015).

798 92. Yolamanova, M. *et al.* Peptide nanofibrils boost retroviral gene transfer and provide a
799 rapid means for concentrating viruses. *Nat. Nanotechnol.* **8,** 130–136 (2013).

800 93. Dai, B. *et al.* Tunable assembly of amyloid-forming peptides into nanosheets as a
801 retrovirus carrier. *Proc. Natl. Acad. Sci.* **112,** 2996–3001 (2015).

802 94. McCarthy, H. O. *et al.* Development and characterization of self-assembling
803 nanoparticles using a bio-inspired amphipathic peptide for gene delivery. *J. Control.*
804 *Release* **189,** 141–9 (2014).

805 95. Udhayakumar, V. K. *et al.* Arginine-Rich Peptide-Based mRNA Nanocomplexes
806 Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic
807 Organization of the Peptide. *Adv. Healthc. Mater.* **6,** 1601412 (2017).

808 96. Douat, C. *et al.* A cell-penetrating foldamer with a bioreducible linkage for intracellular
809 delivery of DNA. *Angew. Chem. Int. Ed. Engl.* **54,** 11133–11137 (2015).

810 97. Gehin, C. *et al.* Dynamic Amphiphile Libraries To Screen for the “Fragrant” Delivery of
811 siRNA into HeLa Cells and Human Primary Fibroblasts. *J. Am. Chem. Soc.* **135,** 9295–
812 9298 (2013).

813 98. Louzao, I., García-Fandiño, R. & Montenegro, J. Hydrazone-modulated peptides for
814 efficient gene transfection. *J. Mater. Chem. B* **5,** 4426–4434 (2017).

815 99. Lostalé-Seijo, I., Louzao, I., Juanes, M. & Montenegro, J. Peptide/Cas9 nanostructures
816 for ribonucleoprotein cell membrane transport and gene edition. *Chem. Sci.* **8,** 7923–
817 7931 (2017).

818 100. Li, M. *et al.* Incorporation of a Non-Natural Arginine Analogue into a Cyclic Peptide
819 Leads to Formation of Positively Charged Nanofibers Capable of Gene Transfection.
820 *Angew. Chemie Int. Ed.* **55,** 598–601 (2016).

821 101. Li, M., Schlesiger, S., Knauer, S. K. & Schmuck, C. A Tailor-Made Specific Anion-Binding
822 Motif in the Side Chain Transforms a Tetrapeptide into an Efficient Vector for Gene
823 Delivery. *Angew. Chemie - Int. Ed.* **54,** 2941–2944 (2015).

824 102. Montenegro, J., Ghadiri, M. R. & Granja, J. R. Ion channel models based on self-
825 assembling cyclic peptide nanotubes. *Acc. Chem. Res.* **46,** 2955–65 (2013).

826 103. Jana, P. *et al.* Efficient Gene Transfection through Inhibition of β-Sheet (Amyloid Fiber)
827 Formation of a Short Amphiphilic Peptide by Gold Nanoparticles. *Angew. Chemie - Int.*
828 *Ed.* **56,** 8083–8088 (2017).

829 104. Freire, J. M. *et al.* siRNA-cell-penetrating peptides complexes as a combinatorial
830 therapy against chronic myeloid leukemia using BV173 cell line as model. *J. Control.*
831 *Release* **245,** 127–136 (2017).

832 105. Felgner, P. L. *et al.* Lipofection: a highly efficient, lipid-mediated DNA-transfection
833 procedure. *Proc. Natl. Acad. Sci.* **84,** 7413–7417 (1987).

834 106. Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: From concept to clinical
835 applications. *Adv. Drug Deliv. Rev.* **65,** 36–48 (2013).

836 107. Oude Blenke, E. E., van den Dikkenberg, J., van Kolck, B., Kros, A. & Mastrobattista, E.
837 Coiled coil interactions for the targeting of liposomes for nucleic acid delivery.
838 *Nanoscale* **8,** 8955–8965 (2016).

839 108. Yang, J. *et al.* Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified
840 Liposomes. *ACS Cent. Sci.* **2,** 621–630 (2016).

841 109. O'Brien, P. J., Elahipanah, S., Rogozhnikov, D. & Yousaf, M. N. Bio-Orthogonal Mediated
842 Nucleic Acid Transfection of Cells via Cell Surface Engineering. *ACS Cent. Sci.* **3,** 489–500
843 (2017).

844 110. Kauffman, K. J. *et al.* Optimization of Lipid Nanoparticle Formulations for mRNA
845 Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. *Nano Lett.*
846 **15,** 7300–7306 (2015).

847 111. Farhood, H., Serbina, N. & Huang, L. The role of dioleoyl phosphatidylethanolamine in
848 cationic liposome mediated gene transfer. *Biochim. Biophys. Acta - Biomembr.* **1235,**
849 289–295 (1995).

850 112. Leal, C., Bouxsein, N. F., Ewert, K. K. & Safinya, C. R. Highly Efficient Gene Silencing
851 Activity of siRNA Embedded in a Nanostructured Gyroid Cubic Lipid Matrix. *J. Am.*
852 *Chem. Soc.* **132,** 16841–16847 (2010).

853 113. Kim, H. & Leal, C. Cuboplexes: Topologically Active siRNA Delivery. *ACS Nano* **9,** 10214–
854 10226 (2015).

855 114. Evers, M. J. W. *et al.* State-of-the-Art Design and Rapid-Mixing Production Techniques
856 of Lipid Nanoparticles for Nucleic Acid Delivery. *Small Methods* 1700375 (2018).
857 doi:10.1002/smtd.201700375

858 115. Whitehead, K. A. *et al.* Degradable lipid nanoparticles with predictable in vivo siRNA
859 delivery activity. *Nat. Commun.* **5,** 4277 (2014).

860 116. Viricel, W. *et al.* Cationic switchable lipids: pH-triggered molecular switch for siRNA
861 delivery. *Nanoscale* **9,** 31–36 (2017).

862 117. Kranz, L. M. *et al.* Systemic RNA delivery to dendritic cells exploits antiviral defence for
863 cancer immunotherapy. *Nature* **534,** 396–401 (2016).

864 118. Oberli, M. A. *et al.* Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer
865 Immunotherapy. *Nano Lett.* **17,** 1326–1335 (2017).

866 119. Liang, C. *et al.* Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a
867 novel RNA interference–based bone anabolic strategy. *Nat. Med.* **21,** 288–294 (2015).

868 120. Ripoll, M. *et al.* pH-Responsive Nanometric Polydiacetylenic Micelles Allow for Efficient
869 Intracellular siRNA Delivery. *ACS Appl. Mater. Interfaces* **8,** 30665–30670 (2016).

870 121. Morin, E., Nothisen, M., Wagner, A. & Remy, J. S. Cationic polydiacetylene micelles for
871 gene delivery. *Bioconjug. Chem.* **22,** 1916–1923 (2011).

872 122. Neuberg, P. *et al.* Polydiacetylenic nanofibers as new siRNA vehicles for in vitro and in
873 vivo delivery. *Nanoscale* **10,** 1587–1590 (2018).

874 123. Jayaraman, M. *et al.* Maximizing the potency of siRNA lipid nanoparticles for hepatic
875 gene silencing in vivo. *Angew. Chemie - Int. Ed.* **51,** 8529–8533 (2012).

876 124. Yim, N. *et al.* Exosome engineering for efficient intracellular delivery of soluble proteins
877 using optically reversible protein–protein interaction module. *Nat. Commun.* **7,** 12277
878 (2016).

879 125. Lee, J. J. *et al.* Cellular Engineering with Membrane Fusogenic Liposomes to Produce
880 Functionalized Extracellular Vesicles. *ACS Appl. Mater. Interfaces* **8,** 6790–6795 (2016).

881 126. O'Loughlin, A. J. *et al.* Functional Delivery of Lipid-Conjugated siRNA by Extracellular
882 Vesicles. *Mol. Ther.* **25,** 1580–1587 (2017).

883 127. Didiot, M.-C. *et al.* Exosome-mediated Delivery of Hydrophobically Modified siRNA for
884 Huntingtin mRNA Silencing. *Mol. Ther.* **24,** 1836–1847 (2016).

885 128. Cui, Z.-K. *et al.* Delivery of siRNA via cationic Sterosomes to enhance osteogenic
886 differentiation of mesenchymal stem cells. *J. Control. Release* **217,** 42–52 (2015).

887 129. Wang, Y. *et al.* A nanoparticle-based strategy for the imaging of a broad range of
888 tumours by nonlinear amplification of microenvironment signals. *Nat. Mater.* **13,** 204–
889 212 (2014).

890 130. Xu, X. *et al.* Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted
891 siRNA Delivery with Robust Anti-Cancer Efficacy. *Angew. Chemie - Int. Ed.* **55,** 7091–
892 7094 (2016).

893 131. Xu, X. *et al.* Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for
894 Prostate Cancer Therapy. *ACS Nano* **11,** 2618–2627 (2017).

895 132. Zhou, J. *et al.* PH-Sensitive Nanomicelles for High-Efficiency siRNA Delivery in Vitro and
896 in Vivo: An Insight into the Design of Polycations with Robust Cytosolic Release. *Nano*
897 *Lett.* **16,** 6916–6923 (2016).

898 133. Chiper, M., Tounsi, N., Kole, R., Kichler, A. & Zuber, G. Self-aggregating 1.8 kDa
899 polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers
900 for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. *J. Control. Release*
901 **246,** 60–70 (2017).

902 134. Cheng, Y., Yumul, R. C. & Pun, S. H. Virus-Inspired Polymer for Efficient In Vitro and In
903 Vivo Gene Delivery. *Angew. Chem. Int. Ed. Engl.* **55,** 12013–7 (2016).

904 135. Cheng, Y. *et al.* Development of switchable polymers to address the dilemma of stability
905 and cargo release in polycationic nucleic acid carriers. *Biomaterials* **127,** 89–96 (2017).

906 136. McKinlay, C. J. *et al.* Charge-altering releasable transporters (CARTs) for the delivery
907 and release of mRNA in living animals. *Proc. Natl. Acad. Sci.* **114,** E448–E456 (2017).

908 137. Chahal, J. S. *et al.* Dendrimer-RNA nanoparticles generate protective immunity against
909 lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.
910 *Proc. Natl. Acad. Sci.* **113,** E4133–E4142 (2016).

911 138. Liu, S. *et al.* Bioreducible Zinc(II)-Coordinative Polyethylenimine with Low Molecular
912 Weight for Robust Gene Delivery of Primary and Stem Cells. *J. Am. Chem. Soc.* **139,**
913 5102–5109 (2017).

914 139. Zou, Y. *et al.* Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA
915 Therapy In Vivo. *Adv. Mater.* **29,** 1–8 (2017).

916 140. Li, L. *et al.* Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in
917 Mice. *ACS Nano* **11,** 95–111 (2017).

918 141. Naito, M. *et al.* A phenylboronate-functionalized polyion complex micelle for ATP-
919 triggered release of siRNA. *Angew. Chemie - Int. Ed.* **51,** 10751–10755 (2012).

920 142. Naito, M. *et al.* Enhanced Intracellular Delivery of siRNA by Controlling ATP-
921 Responsivity of Phenylboronic Acid-Functionalized Polyion Complex Micelles.
922 *Macromol. Biosci.* **18,** 1700357 (2018).

923 143. Yoshinaga, N. *et al.* Polyplex Micelles with Phenylboronate/Gluconamide Cross-Linking
924 in the Core Exerting Promoted Gene Transfection through Spatiotemporal Responsivity
925 to Intracellular pH and ATP Concentration. *J. Am. Chem. Soc.* **139,** 18567–18575 (2017).

926 144. Truong, N. P. *et al.* An influenza virus-inspired polymer system for the timed release of
927 siRNA. *Nat. Commun.* **4,** 1902 (2013).

928 145. Wang, M., Liu, H., Li, L. & Cheng, Y. A fluorinated dendrimer achieves excellent gene
929 transfection efficacy at extremely low nitrogen to phosphorus ratios. *Nat. Commun.* **5,**
930 3053 (2014).

931 146. Wang, H. *et al.* Self-Assembled Fluorodendrimers Combine the Features of Lipid and
932 Polymeric Vectors in Gene Delivery. *Angew. Chemie - Int. Ed.* **54,** 11647–11651 (2015).

933 147. Wang, L.-H., Wu, D.-C., Xu, H.-X. & You, Y.-Z. High DNA-Binding Affinity and Gene-
934 Transfection Efficacy of Bioreducible Cationic Nanomicelles with a Fluorinated Core.
935 *Angew. Chemie Int. Ed.* **55,** 755–759 (2016).

936 148. Zhang, Z. *et al.* The fluorination effect of fluoroamphiphiles in cytosolic protein delivery.
937 *Nat. Commun.* **9,** 1377 (2018).

938 149. Davis, M. E. The First Targeted Delivery of siRNA in Humans via a Nanoparticle : From
939 Concept to Clinic. *Mol. Pharm.* **6,** 659–668 (2009).

940 150. Maity, S., Choudhary, P., Manjunath, M., Kulkarni, A. & Murthy, N. A biodegradable
941 adamantane polymer with ketal linkages in its backbone for gene therapy. *Chem.*
942 *Commun.* **51,** 15956–15959 (2015).

943 151. Chen, X., Qiu, Y.-K., Owh, C., Loh, X. J. & Wu, Y.-L. Supramolecular cyclodextrin

944 nanocarriers for chemo- and gene therapy towards the effective treatment of drug
945 resistant cancers. *Nanoscale* **8,** 18876–18881 (2016).

946 152. Eldredge, A. C., Johnson, M. E., Oldenhuis, N. J. & Guan, Z. Focused Library Approach to
947 Discover Discrete Dipeptide Bolaamphiphiles for siRNA Delivery. *Biomacromolecules* **17,**
948 3138–3144 (2016).

949 153. Yan, Y. *et al.* Functional polyesters enable selective siRNA delivery to lung cancer over
950 matched normal cells. *Proc. Natl. Acad. Sci.* **113,** E5702–E5710 (2016).

951 154. Hao, J. *et al.* Rapid Synthesis of a Lipocationic Polyester Library via Ring-Opening
952 Polymerization of Functional Valerolactones for Efficacious siRNA Delivery. *J. Am. Chem.*
953 *Soc.* **137,** 9206–9209 (2015).

954 155. Priegue, J. M. *et al.* In Situ Functionalized Polymers for siRNA Delivery. *Angew. Chemie -*
955 *Int. Ed.* **55,** 7492–7495 (2016).

956 156. Priegue, J. M. *et al.* Different-Length Hydrazone Activated Polymers for Plasmid DNA
957 Condensation and Cellular Transfection. *Biomacromolecules* acs.biomac.8b00252
958 (2018). doi:10.1021/acs.biomac.8b00252

959 157. Zhao, Y. *et al.* PolyMetformin combines carrier and anticancer activities for in vivo
960 siRNA delivery. *Nat. Commun.* **7,** 11822 (2016).

961 158. Lyu, Y. *et al.* Dendronized Semiconducting Polymer as Photothermal Nanocarrier for
962 Remote Activation of Gene Expression. *Angew. Chemie - Int. Ed.* **56,** 9155–9159 (2017).

963 159. Tan, Z., Dhande, Y. K. & Reineke, T. M. Cell Penetrating Polymers Containing
964 Guanidinium Trigger Apoptosis in Human Hepatocellular Carcinoma Cells unless
965 Conjugated to a Targeting N-Acetyl-Galactosamine Block. *Bioconjug. Chem.* **28,** 2985–
966 2997 (2017).

967 160. Liu, Y., Wenning, L., Lynch, M. & Reineke, T. M. New poly(D-glucaramidoamine)s induce
968 DNA nanoparticle formation and efficient gene delivery into mammalian cells. *J. Am.*
969 *Chem. Soc.* **126,** 7422–7423 (2004).

970 161. Dong, Y. *et al.* Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic
971 siRNA and mRNA Delivery in Vivo. *Nano Lett.* **16,** 842–848 (2016).

972 162. Kaczmarek, J. C. *et al.* Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to
973 the Lungs. *Angew. Chemie - Int. Ed.* **55,** 13808–13812 (2016).

974 163. Li, J. *et al.* Structurally Programmed Assembly of Translation Initiation Nanoplex for
975 Superior mRNA Delivery. *ACS Nano* **11,** 2531–2544 (2017).

976 164. Hong, C. A. *et al.* Dendrimeric siRNA for Efficient Gene Silencing. *Angew. Chem. Int. Ed.*
977 *Engl.* **54,** 6740–4 (2015).

978 165. Smith, T. T. *et al.* In situ programming of leukaemia-specific T cells using synthetic DNA
979 nanocarriers. *Nat. Nanotechnol.* **12,** 813–820 (2017).

980 166. Graham, F. L. L. & van der Eb, A. J. J. A new technique for the assay of infectivity of
981 human adenovirus 5 DNA. *Virology* **52,** 456–67 (1973).

982 167. Hong, G., Diao, S., Antaris, A. L. & Dai, H. Carbon Nanomaterials for Biological Imaging
983 and Nanomedicinal Therapy. *Chem. Rev.* **115,** 10816–10906 (2015).

984 168. Pantarotto, D. *et al.* Functionalized carbon nanotubes for plasmid DNA gene delivery. *Angew. Chem. Int. Ed. Engl.* **43,** 5242–6 (2004).

986 169. Battigelli, A. *et al.* Ammonium and guanidinium dendron-carbon nanotubes by amidation and click chemistry and their use for siRNA delivery. *Small* **9,** 3610–3619 (2013).

989 170. Kam, N. W. S., Liu, Z. & Dai, H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. *J. Am. Chem. Soc.* **127,** 12492–12493 (2005).

992 171. Wang, J. T. W. *et al.* The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo. *Biomaterials* **35,** 9517–9528 (2014).

995 172. Cifuentes-Rius, A. *et al.* In Vivo Fate of Carbon Nanotubes with Different Physicochemical Properties for Gene Delivery Applications. *ACS Appl. Mater. Interfaces* **9,** 11461–11471 (2017).

998 173. Munk, M. *et al.* Efficient delivery of DNA into bovine preimplantation embryos by multiwall carbon nanotubes. *Sci. Rep.* **6,** 33588 (2016).

1000 174. Maeda-Mamiya, R. *et al.* In vivo gene delivery by cationic tetraamino fullerene. *Proc. Natl. Acad. Sci.* **107,** 5339–5344 (2010).

1002 175. Sigwalt, D. *et al.* Gene delivery with polycationic fullerene hexakis-adducts. *Chem. Commun.* **47,** 4640–2 (2011).

1004 176. Wang, J. *et al.* Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo. *Acta Biomater.* **59,** 158–169 (2017).

1007 177. Dowaidar, M., Abdelhamid, H. N., Hällbrink, M., Zou, X. & Langel, Ü. Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. *Biochim. Biophys. Acta - Gen. Subj.* **1861,** 2334–2341 (2017).

1010 178. Chu, Z. *et al.* Rapid endosomal escape of prickly nanodiamonds: implications for gene delivery. *Sci. Rep.* **5,** 11661 (2015).

1012 179. Lim, D. G. *et al.* Polyamidoamine-Decorated Nanodiamonds as a Hybrid Gene Delivery Vector and siRNA Structural Characterization at the Charged Interfaces. *ACS Appl. Mater. Interfaces* **9,** 31543–31556 (2017).

1015 180. Zhang, X. Q. *et al.* Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. *ACS Nano* **3,** 2609–2616 (2009).

1017 181. Chen, M. *et al.* Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. *J. Phys. Chem. Lett.* **1,** 3167–3171 (2010).

1019 182. Yi, Y. *et al.* Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles. *J. Control. Release* **244,** 247–256 (2016).

1022 183. Conde, J., Oliva, N., Zhang, Y. & Artzi, N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. *Nat. Mater.* **15,**

1024 1128–1138 (2016).

1025 184. Lei, Y. *et al.* Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of
1026 pancreatic cancer. *Nat. Commun.* **8,** 15130 (2017).

1027 185. Cutler, J. I., Auyeung, E. & Mirkin, C. A. Spherical nucleic acids. *J. Am. Chem. Soc.* **134,**
1028 1376–1391 (2012).

1029 186. Randeria, P. S. *et al.* siRNA-based spherical nucleic acids reverse impaired wound
1030 healing in diabetic mice by ganglioside GM3 synthase knockdown. *Proc. Natl. Acad. Sci.*
1031 *U. S. A.* **112,** 5573–5578 (2015).

1032 187. Sita, T. L. *et al.* Dual bioluminescence and near-infrared fluorescence monitoring to
1033 evaluate spherical nucleic acid nanoconjugate activity in vivo. *Proc. Natl. Acad. Sci.* **114,**
1034 4129–4134 (2017).

1035 188. Li, N. *et al.* Nuclear-targeted siRNA delivery for long-term gene silencing. *Chem. Sci.* **8,**
1036 2816–2822 (2017).

1037 189. Rouge, J. L. *et al.* Ribozyme–Spherical Nucleic Acids. *J. Am. Chem. Soc.* **137,** 10528–
1038 10531 (2015).

1039 190. Ruan, W. *et al.* DNA nanoclew templated spherical nucleic acids for siRNA delivery.
1040 *Chem. Commun.* **54,** 3609–3612 (2018).

1041 191. Calabrese, C. M. *et al.* Biocompatible infinite-coordination-polymer nanoparticle-
1042 nucleic-acid conjugates for antisense gene regulation. *Angew. Chem. Int. Ed. Engl.* **54,**
1043 476–480 (2015).

1044 192. Banga, R. J., Chernyak, N., Narayan, S. P., Nguyen, S. T. & Mirkin, C. A. Liposomal
1045 spherical nucleic acids. *J. Am. Chem. Soc.* **136,** 9866–9869 (2014).

1046 193. Li, H. *et al.* Molecular spherical nucleic acids. *Proc. Natl. Acad. Sci. U. S. A.* **115,** 4340–
1047 4344 (2018).

1048 194. Möller, K. *et al.* Highly efficient siRNA delivery from core–shell mesoporous silica
1049 nanoparticles with multifunctional polymer caps. *Nanoscale* **8,** 4007–4019 (2016).

1050 195. Shen, J. *et al.* High Capacity Nanoporous Silicon Carrier for Systemic Delivery of Gene
1051 Silencing Therapeutics. *ACS Nano* **7,** 9867–9880 (2013).

1052 196. Kapilov-Buchman, Y., Lellouche, E., Michaeli, S. & Lellouche, J. P. Unique surface
1053 modification of silica nanoparticles with polyethylenimine (PEI) for siRNA delivery using
1054 cerium cation coordination chemistry. *Bioconjug. Chem.* **26,** 880–889 (2015).

1055 197. Shen, J. *et al.* Multi-step encapsulation of chemotherapy and gene silencing agents in
1056 functionalized mesoporous silica nanoparticles. *Nanoscale* **9,** 5329–5341 (2017).

1057 198. He, C., Lu, K., Liu, D. & Lin, W. Nanoscale metal-organic frameworks for the co-delivery
1058 of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian
1059 cancer cells. *J. Am. Chem. Soc.* **136,** 5181–5184 (2014).

1060 199. Chen, Q. *et al.* Se/Ru-Decorated Porous Metal-Organic Framework Nanoparticles for
1061 the Delivery of Pooled siRNAs to Reversing Multidrug Resistance in Taxol-Resistant
1062 Breast Cancer Cells. *ACS Appl. Mater. Interfaces* **9,** 6712–6724 (2017).

1063 200. Thierry, A. R. *et al.* Characterization of liposome-mediated gene delivery: Expression,
1064 stability and pharmacokinetics of plasmid DNA. *Gene Ther.* **4,** 226–237 (1997).

1065 201. Tsui, N. B. Y., Ng, E. K. O. & Lo, Y. M. D. Stability of endogenous and added RNA in blood
1066 specimens, serum, and plasma. *Clin. Chem.* **48,** 1647–1653 (2002).

1067 202. Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of
1068 drugs. *Nat. Rev. Drug Discov.* **13,** 759–780 (2014).

1069 203. Layzer, J. M. *et al.* In vivo activity of nuclease-resistant siRNAs. *RNA* **10,** 766–71 (2004).

1070

1071

1072 **Highlighted references**

1073 Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical
1074 utility. *Nat. Biotechnol.* **35,** 238–248 (2017).
1075 ***This review provides a comprehensive overview of the chemical modification of**
1076 **oligonucleotides of medical interest.**

1077 Meade, B. R. *et al.* Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing
1078 phosphotriester backbone modifications. *Nat. Biotechnol.* **32,** 1256–1261 (2014).
1079 ***This study presents a method for the efficient production of phosphotriester nucleic acid**
1080 **derivatives with excellent targeting and delivery properties.**

1081 Lee, K. *et al.* In vivo delivery of transcription factors with multifunctional oligonucleotides. *Nat.*
1082 *Mater.* **14,** 701–706 (2015).
1083 ***This paper presents a procedure for the delivery of transcription factors using**
1084 **oligonucleotides modified with pH responsive constructs.**

1085 Li, M., Schlesiger, S., Knauer, S. K. & Schmuck, C. A Tailor-Made Specific Anion-Binding Motif in
1086 the Side Chain Transforms a Tetrapeptide into an Efficient Vector for Gene Delivery.
1087 *Angew. Chemie Int. Ed.* **54,** 2941–2944 (2015).
1088 *** This article introduces the new guanidinocarbonyl pyrrole group for nucleic acids delivery.**

1089 O'Brien, P. J., Elahipanah, S., Rogozhnikov, D. & Yousaf, M. N. Bio-Orthogonal Mediated Nucleic
1090 Acid Transfection of Cells via Cell Surface Engineering. *ACS Cent. Sci.* **3,** 489–500 (2017).
1091 *** This study describes a method for the application of bio-orthogonal chemistry to the fusion**
1092 **of liposomes.**

1093 Lee, J. J. *et al.* Cellular Engineering with Membrane Fusogenic Liposomes to Produce
1094 Functionalized Extracellular Vesicles. *ACS Appl. Mater. Interfaces* **8,** 6790–6795 (2016).
1095 *** In this article, a versatile method for the chemical functionalization of exosomes is**
1096 **described.**

1097 Zhou, J. *et al.* PH-Sensitive Nanomicelles for High-Efficiency siRNA Delivery in Vitro and in Vivo:
1098 An Insight into the Design of Polycations with Robust Cytosolic Release. *Nano Lett.* **16,**
1099 6916–6923 (2016).
1100 *** This article focuses on the properties required to maximize release in conditions of very**
1101 **low uptake.**

1102 McKinlay, C. J. *et al.* Charge-altering releasable transporters (CARTs) for the delivery and
1103 release of mRNA in living animals. *Proc. Natl. Acad. Sci.* **114,** E448–E456 (2017).
1104 * **This study describes a self-immolative polymer that is able to deliver mRNA in primary cells**
1105 **and *in vivo.***

1106 Smith, T. T. *et al.* In situ programming of leukaemia-specific T cells using synthetic DNA
1107 nanocarriers. *Nat. Nanotechnol.* **12,** 813–820 (2017).
1108 *** In this article, a method for the *in situ* modification of T-cells for cancer immunotherapy is**
1109 **shown.**

1110 Li, N. *et al.* Nuclear-targeted siRNA delivery for long-term gene silencing. *Chem. Sci.* **8,** 2816–
1111 2822 (2017).
1112 *** This paper shows the impact that subcellular distribution of the cargo has in the duration**
1113 **of the silencing.**

1114